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Abstract 
 This work describes the studies on the development of new cyclodextrin-hydrogel systems in 
supercritical carbon dioxide (scCO2) with potential application in drug delivery. Three β-cyclodextrin 
(CDs) derivatives were synthesized: 6-monoacryloyl-β-CD, 2-monoacryloyl-β-CD and 6-monoacryloly-
heptakis-(2,3-di-O-benzyl)-β-CD. Their structures were assigned by nuclear magnetic resonance (NMR), 
infrared (IR) and mass spectrometry (MS) using the technique of matrix-assisted laser 
desorption/ionisation-time-of-flight (MALDI-TOF).  These functionalized β-CDs were co-polymerized in 
scCO2 and the resulting co-polymers were characterized by high resolution magnetic angle spinning (HR-
MAS) NMR. Swelling tests were performed showing that the presence of CD decreases the swelling 
capacity of the corresponding co-polymers. The β-CD co-polymers were impregnated with a model drug, 
metronidazole, using a batch supercritical fluid impregnation process. Experiments in vitro were realized 
in order to evaluate the performance of the cyclodextrin-hydrogel system as drug release device at 
different pHs, 2.2 and 7.4. The co-polymer with 2.5 % of 2-monoacryloyl-β-CD was the one that 
impregnated more drug and showed more interesting results, since at pH 2.2 the release is more 
controlled. The effect of the percentage of β-CD in the co-polymers performance was also investigated. 
The co-polymer with more percentage of 2-monoacryloyl-β-CD (8.8%) showed a more controlled drug 
release at pH 7.4. The results with 2.5 % of β-CD indicate that the co-polymer would be more suitable for 
oral administration, whereas with 8.8 % would be suitable for parenteral administration. 
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Resumo 
Este trabalho descreve os estudos realizados no desenvolvimento de sistemas de ciclodextrinas (CDs)-
hidrogel, em dióxido de carbono supercrítico com potencial aplicação para a libertação controlada de 
fármacos. Três derivados de β-CDs foram sintetizados: 6-monoacrilada-β-CD, 2-monoacrilada-β-CD e a 
6-monoacrilada-hepta-(2,3-di-O-benzilo)-β-CD. As suas estruturas foram determinadas por ressonância 
magnética nuclear, infravermelho e espectrometria de massa através da técnica de MALDI-TOF. As β-
CDs funcionalizadas foram co-polimerizadas em dióxido de carbono supercrítico e os resultantes co-
polímeros foram caracterizados por ressonância magnética nuclear usando a técnica de HR-MAS. Foram 
realizados testes de swelling que demonstraram que a presença da β-CD nos co-polímeros diminui o 
swelling. Os co-polímeros da β-CD foram impregnados com um fármaco, o metronidazol, usando um 
processo de impregnação em dióxido de carbono supercrítico. Realizaram-se estudos in vitro com o intuito 
de avaliar a performance do sistema CDs-hidrogel para a libertação controlada do metronidazole a pH 2.2 
e a pH 7.4. O co-polímero com 2.5 % de 2-monoacrilada-β-CD foi o que conseguiu impregnar mais 
metronidazol e também aquele que demonstrou um resultado mais interessante, uma vez que a pH 2.2 teve 
uma libertação mais controlada do fármaco. A percentagem de β-CD nos co-polímeros também foi um 
factor estudado. O co-polímero com mais percentagem de 2-monoacrilada-β-CD (8.8 %) apresentou uma 
libertação do fármaco mais controlada a pH 7.4. Os resultados indicam que o co-polímero com 2.5 % de 
2-monoacrilada-β-CD será mais adequado para uma aplicação futura por administração oral e o co-
polímero com 8.8 % de 2-monoacrilada-β-CD será mais adequado para administração parenteral. 
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1. Introduction 
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1.1 Cyclodextrins 
In 1981, A. Villiers, a French scientist, reported the formation of a crystalline 
substance by fermentation of starch and determined its composition as (C6H10O5)2.3H2O 
naming it as “cellulosine”.[1-3] 
In 1903, an Austrian microbiologist, Franz Schardinger, isolated from the 
microorganism Bacillus macerans, two distinct crystalline substances and identified them 
as a cyclic structure of glucose oligomers, called α-cyclodextrin (CD) and β-CD. In 1935, 
γ-CD was discovered by Freudenberg and Jacobi.[1, 2, 4] 
The corrected chemical structure of α-, β-, γ-CD was elucidated by Freudenberg and 
co-workers in 1938, featuring them as cyclic structures composed of α-1,4-linked glucose 
units (Figure 1.1). In the following years their molecular weight was determined.
[1, 5, 6] 
 
 
Figure 1.1: Generic representation of the structure of the different types of CD. 
In 1953 the first patent on CD and their inclusion complex ability was registered by 
Freudenberg, Cramer and Plieninger, who recognize the potential of these compounds to 
form complexes. Later, in the 70s, only a small amount of CD could be produced with a 
high production cost. However, advances in the biotechnology field allowed the 
improvement of CDs production in terms of costs and purity.
[2]
 
Using genetic engineering techniques, highly active and specific enzymes, 
cyclodextrin glucosyltransferases (GCTases) were isolated, which can selectively 
produce CD subtypes. Nowadays, the use of these enzymes as well as the progress in 
purification processes, has been leading to production of high yields of pure CD subtypes 
on large scale.
[2, 7-9] 
  
3 
 
Figure 1.2 summarizes the main CDs development phases: the discovery period, the 
exploratory period, and the utilization period.
 [2, 7-9] 
  
 
Figure 1.2: CDs history, by József Szejtli.
[9]
 
 
1.1.1 Fundamentals of CD chemistry 
CDs also known as cycloamyloses, cyclomaltoses or Schardinger dextrins, are macrocyclic 
oligosaccharides, most commonly composed by 6, 7 or 8 D-glucose units, known as α-, β- and γ-
CD, respectively (Figure 1.3).
[8, 9]
 These CDs are crystalline and homogeneous substances, built 
up from glucopyranose units.
[8, 9] 
 
Figure 1.3: Structure of α (1)-, β (2)- and γ-CD (3).[8] 
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The most important properties of CDs are summarized in Table 1.1.
[1, 5, 8-10]
 
Table 1.1: Properties of α-, β- and γ-CD.[5] 
 α-CD β-CD γ-CD 
Number of glucose units 6 7 8 
Molecular weight 972 1134 1296 
Approximate inner cavity diameter (pm) 50 620 800 
Approximate outer diameter (pm) 1460 1540 1750 
Approximate volume of cavity (10
6
 pm
3
) 174 262 427 
[α]D at 25ºC 150.0 ± 0.5 162.5 ± 0.5 177.4 ± 0.5 
Solubility in water (room temperature, g/100 
ml) 
14.5 1.85 23.2 
Melting temperature range (ºC) 255-260 255-265 240-245 
Water molecules in cavity 6 11 17 
 
The units of D-glucose are attached by α-1,4-linkages, and the rigid 4C1-chair conformation 
gives to the macrocycle structure the shape of a hollow truncated cone.
[5]
 The hydroxyl groups 
located at the outer surface of the CD molecule are the primary hydroxyl groups that are located 
at the narrow face of the cone, while the secondary hydroxyls are located at the wide face, Figure 
1.4. The cone is formed by the carbon skeletons of the glucose units and the glycosidic oxygen 
atoms in between.
[1, 6, 8] 
 
Figure 1.4: Schematic 3D representation of CD.
[8]
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The C2-OH group of glucopyranoside unit can form a hydrogen bond with the C3-OH group 
of the adjacent glucopyranose unit, forming a complete secondary belt, which may explain the 
rigid structure of β-CD and the lower water solubility comparing with the other CDs (Table 
1.1).
[5, 9, 11] 
In Table 1.1, it is possible to observe the different size and diameter of the cavities 
from the different CDs.
[5, 8, 9]
 
The primary hydroxyl groups on the outside of the CDs cavity make them soluble in water, 
but simultaneously the secondary hydroxyl groups generate a cavity that is relatively 
hydrophobic
[8, 9]
  or  lipophilic
[12, 13]
  (Figure 1.4).  
 
1.1.2 Chemical Modification of CDs 
The strategies for selective modification of CDs explored to date involve the exploration of 
the different reactivity of hydroxyl groups in CDs, and the selective modification is often 
adverted by regioselective protection and deprotection sequential steps.
[6, 11, 14]
 
All modifications of CDs take place at the hydroxyl groups (C2-OH, C3-OH and C6-OH), 
which nucleophilic nature directs the regioselectivity and extension of modifications on all 
subsequent reactions.
[14, 15]
 
The glucose units of CDs contain three different types of hydroxyl groups: primary hydroxyl 
groups at position C6, and secondary hydroxyl groups at C2 and C3. The primary side C6-OH 
groups are the most basic and the most nucleophilic, the C2-OH groups are the most acidic and 
the C3-OH groups are the most inaccessible.
[5, 14-16]
 The different reactivity between both 
secondary hydroxyl groups is due to the fact that C2-OH is closer to the hemi-acetal than the C3-
OH.
[5, 14]
 
Some of the reported methods to functionalize CDs will be described next. 
 
1.1.2.1 Modification at the primary face 
The primary hydroxyl groups are the easiest to modify due to their high nucleophilicity and 
accessibility. Selective permodification of all the primary hydroxyl groups is relatively easier 
than mono- or disubstitution, because persubstitution is achieved when the reaction is allowed to 
run for a longer time with appropriate amounts of reagents. Normally, these products require 
chromatographic purification.
[5, 11, 14] 
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Permodification at the C6-Position 
Opposite to the mono-substitution of CDs, the persubstitution at C6 such as the persulfonates 
derivates are normally prepared directly from CDs by treatment with a large amount of sulfonyl 
chloride in pyridine. The 6-position tend to change to the 3,6-anhydro form, even in the absence 
of a base at room temperature (Figure 1.5).
[14]
 This represents a limitation to this method, and in 
order to get reproducible results, the use of freshly prepared persulfonates is required.
[14] 
 
 
Figure 1.5: Conversion of a 6-substituted CD to a 3,6-anhydro CD. X is a good leaving group.
[14]
  
Another approach reports for pertosylation or –mesylation involves silylation at the primary 
side of CDs with the TBDMS group (Figure 1.6, 4) as the first step, followed by esterification of 
the secondary side, subsequent desilylation and finally tosylation at the primary side (Figure 1.6, 
I-IV).
 [14, 17]
 
 
Figure 1.6: Strategies for pertosylation (I-IV) and peralkylation (I-VI). R1: TBDMS, R2: methyl or acetyl 
group, R3: alkyl group.
 [14] 
Peralkylation of the primary hydroxyl groups is not direct and requires many synthetic steps. 
The strategy consists on the protection of the primary face with silyl groups as the first step, 
followed by esterification of the secondary face, subsequent desilylation, and finally reaction with 
an alkyl halide, under strongly basic conditions to produce the alkyl ether (Figure 1.6, I-VI).
[14] 
Indeed, the per-O-6-silylated (Figure 1.6, 4) CDs are extremely useful and are widely used in 
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multi-step sequences, due to the good stability and easy removal of the silyl protecting groups.
 [14, 
18]
 
Per 6-halogenocyclodextrins are important classes of compounds that, due to their greater 
stability compared to per-6-sulfonates, can be used for the selective functionalization of the 
primary face. However, these compounds are only soluble in polar solvents such as pyridine, 
N,N’-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), among others. [14] The secondary 
side of halogenated CDs can be acetylated in order to increase the solubility or allow a more 
selective functionalization (Figure 1.7).
 [14]
 
 
Figure 1.7: Strategy for synthesis of per-6-substituted CD via halogenated CD. X: Halogen atoms. R: 
Alkoxy, alkylamino, thio.
 [14]
 
Monosubstitution at C-6-position 
The most popular method for monomodifications at the 6-position of CDs is by nucleophilic 
attack to a properly functionalized CD, for example containing a good leaving group such as the 
tosyl group.
 [14, 16]
 The three main functional groups used for a variety of modification in CDs are 
the 6-tosyl (5), the 6-azide (6) and the 6-aldehydic (7) β-CDs (Figure 1.8). [5, 14] One of the most 
commonly used methods to perform mono-functionalizations at C6-OH is via the monotosyl CD 
(Figure 1.8, I), which formation involves treatment of CD with tosyl chloride in pyridine or 
DMF.
 [14, 16, 19-21]
 However, this reaction produces a mixture of mono, di and tri-tosylated CDs. In 
order to obtain the desired product an extensive purification is required leading to low product 
yields.
 
This compound is an important intermediate to achieve other desired modified products 
(Figure 1.8, II). 
[14, 16]
 
Many derivatives can be obtained from 6-monotosyl CD (5) by nucleophilic displacement of 
the tosyl group by a suitable nucleophile such as iodide, azide, thioacetate, hydroxylamine, alkyl, 
among others. This reaction allows the selective introduction of new functionalities at this 
position (Figure 1.8, II).
 [14, 15] 
The 6-monoazide CD (6) can be obtained by two different methods: via the 6-monotosyl CD 
(5) under heating with sodium or lithium azide salt in DMF (Figure 1.8, V); or via the Vilsmeier-
Haack type reactions in which the CDs are heated with sodium azide containing 
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triphenylphosphine in DMF (Figure 1.8, III). The 6-monoazide CD (6) derivative is often used to 
obtain the 6-monoamine (8).
[5, 14]
 
 
 
Figure 1.8: Summary of several pathways for the monosubstituion at 6-position of CDs. R1= I
-
, N3
-
, 
alkyl.
[14]
 
6-Monoaldehydic CDs (7) provide another route for further modifications (Figure 8, VI). The 
6-monoaldehyde (7) has been synthesized by oxidizing 6-monotosyl-β-CD (5) using DMSO 
(Figure 1.8, VIII) or directly synthesized by reacting CDs with Dess-Martin periodinane (DMP), 
with a high yield (Figure 1.8, VI). Oxidation of 6-monoaldehyde (7) leads to the corresponding 
carboxylic acid (9) (Figure 1.8, VII).
 [5, 14]
 
 
1.1.2.2 Modification reaction at the secondary face 
The secondary side is very important, especially to allow studies about the influence and role 
of the CD cavity. At the secondary side, the hydrogen bonding between hydroxyl groups at C2-
OH and C3-OH positions makes them rigid and less flexible when compared with the primary C6-
OH hydroxyl groups.
[11]
 All these factors make the secondary side less reactive and harder to 
selectively functionalize, comparing to the primary face.
[11]
 During the course of a reaction, as the 
degree of substitution increases, the secondary side becomes more crowded. This results in steric 
hindrance for the incoming nucleophile, which forces the attacking group toward the other 
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position, decreasing the selectivity. Positional isomerism in the secondary side, contributes to an 
increase in complexity.
 [5, 14]
 
 
Permodification at the C2-Position 
Selective perfuncionalization of the secondary side is a difficult process due to the higher 
reactivity of the primary hydroxyl groups. A strong base selectively produces a 2-alcoxide ion 
which reacts with alkyl or sulfonyl chloride (Figure 1.8, I). This discriminatory behavior becomes 
less significant with increasing degree of substitution due to the steric crowding, where, as the 
reaction proceeds, the incoming electrophile finds the attack at the available primary hydroxyl 
groups more attractive. This problem can be overcomed by protecting the primary face of CDs 
with suitable group such as TBDMS (Figure 1.9, II).
 [5, 14]
 
 
Figure 1.9: Strategies for modifications at the 2-positions of CDs. R: Sulfonly group, R:  R1:TBDMS.
 [14]
 
In order to prepare per-2-sulfonylation of CDs it is necessary to protect the primary hydroxyl 
groups due to their higher reactivity. The silyl group is usually selected as protecting group due to 
its easy removal with tetra-n-butylamonium fluoride (TBAF) (Figure 1.9, IV). After protection of 
the primary side, the product of per-2-tosylation is prepared by using tosyl chloride as reagent and 
pyridine as solvent. Subsequent desilylation affords the desired compound (Figure 1.9, III-IV). 
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Due to the tendency to form 2,3-epoxy (Figure 1.9, V) derivatives in the basic medium,
 
the yield 
of tosylation reaction is low.
 [14]
  
The direct alkylation of CDs at C2-OH is scarcely reported in literature, but an interesting 
approach has been described for the synthesis of per-2-alkylated CDs. This strategy involved the 
alkylation of per-2,6-di-O-TBDMS CD, due to the migratory property of the silyl group (from O-
2 to O-3). The per-2-alkylated compound was obtained after removal of the silyl groups from 
positions O-3 and O-6.
 [14] 
 
Per-modification at the C3-Position 
The hydroxyl groups at the C3 are the least reactive groups, probably because of the hydrogen 
bonding with C2 hydroxyl groups. This position is hardly accessed and less reactive; consequently 
the modification in this position is not easy.
 [5, 14]
 
Selective per-3-sulfonation has not yet been reported, since sulfonyl chlorides fail to react 
with C3-OH hydroxyl groups. Indeed, strategies that involve protection of O-2- and O-6 positions 
with TBDMS, lead to a high steric hindrance due to the bulky silyl functionality.
[17] 
Moreover, the 
TBDMS groups have a tendency to migrate from the O-2 to O-3-hydroxyl groups under strongly 
basic conditions, which also limits the attack of O-3-hydroxyl groups to the sulfonyl reagent.
 [17]
 
The use of TMS group for protection at the O-2- and O-6 positions does not constitute a better 
choice, since these groups are easily hydrolyzed under neutral or acidic conditions.
[14]
 Per-2-
sulfonated CDs, when under basic condition, lead to per-2,3-epoxy-CDs (Figure 1.9, V).
 [14]
 
 
1.1.3 NMR Studies 
To perform an analysis and structural assignment of each monomer and polymer of CD, it is 
important to be familiar with NMR of non-functionalized β-CD. 
The NMR spectroscopy has become the most important tool for structural elucidation of 
organic compounds. This technique allows structural assignment of compounds obtained by 
synthetic modifications in the different units of glucose of CD, by different 2D NMR 
experiments.
[11, 22]
 
In the 
1
H-NMR spectra it is possible to identifie most of the CD protons, facilitated by the 
high symmetry of these macrocycles (Figure 1.10).
 [11, 22]
 The solvents have an influence in the 
1
H-NMR spectra, due to fast exchange of OH protons, in the case of D2O and DMSO-d6 as a 
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solvent. These different solvents allow a detailed insight into the intramecular CDs hydrogen-
bond network.
[22] 
 
Figure 1.10: Representation of chemical shift spectra of β-CD: A- in D2O and B- in DMSO-d6. C- Structure 
of the β-CD numbered.[22]  
In protic solvents such as D2O, intermolecular exchange between solute and solvent is too 
fast on the NMR time scale for the observation of separate OH signals. The intramolecular 
hydrogen bond is visible by hydrogen-deuterium exchange rate constants in D2O for the 
equilibrium:
 [22] 
 
In a solvent such as DMSO-d6 it is possible to observe separate signals for the OH groups and 
analyze the coupling of the vicinal C-H protons. The resonances of C3-OH and C2-OH were 
found to appear in DMSO-d6 between 5.4 and 5.6 ppm, clearly separated from the signals of the 
free, more shielded OH-6 group at 4.3 ppm (Figure 1.10, b). In DMSO-d6 as hydrogen bonding 
acceptor, the following hydrogen-bonding equilibrium is present:
 [22]
 
 
The left side stands for intramolecular hydrogen bonds in the CD, while the right side for the 
solvent-solute association.
 [22]
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1.1.4 CD inclusion complexes in aqueous solution 
Each CD has its own characteristics to form inclusion complexes with specific molecules, 
which is determined by the characteristics of the guest molecules, such as polarity, size and 
geometry that should be appropriate to the hydrophobicity and cavity size of a particular CD.
[23]
 
In an aqueous solution, the slightly apolar CD cavity is occupied by water molecules which 
are energetically unfavored (polar-apolar interaction) and can be readily substituted by an 
appropriate guest molecule less polar than water (Figure 1.11).
[7, 9, 10, 15]
 The dissolved CD is the 
“host” molecule and the driving force for complex formation is the substitution of the high-
enthalpy water molecules by an appropriate guest molecule (Figure 1.11).
[7, 10, 24]
 
 
Figure 1.11: Schematic representation of CD inclusion complex formation. The guest molecule is p-Xylene 
and small circles represent the water molecules.
[7]
 
Frequently, the host:guest ratio is 1:1, however, 1:2, 2:1, 2:2 or other association can occur, 
sometimes simultaneously (Figure 1.12).
[9, 24]
 
 
Figure 1.12: Schematic illustration of the association of free CD and drug to form drug-CD complexes.
[23]
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The cavity size of α-CD allows the formation of complexes with aliphatic chains and small 
molecules, whereas β-CD is appropriate for aromatic ring and γ-CD has a larger cavity so can 
form complexes with larger molecules, as steroids.
 [23, 25]
 
Upon dissolving these complexes, an equilibrium is established between dissociated and 
associated species, and this is expressed by the complex stability constant Kc. The association of 
the CD and guest (D) molecules, and the dissociation of the formed CD/guest complex is 
governed by the thermodynamic equilibrium (Figure 1.13).
[9, 15] 
 
     
      
       
 
Figure 1.13: Representation of the equilibrium constant of inclusion complexes.
[15]
  
This association and dissociation reactions of guest molecules from the CDs are dynamic 
processes that occur quite fast (in few milliseconds), even for complexes with high stability 
constants.
 [23]
 According to this properties, the kinetics of drug release from CDs will not be a 
limiting factor in absorption,
 
other mechanisms may also be responsible for the release of the 
drug inclusion complex, as the effect of pH on CDs or ionizable drugs.
 [23]
 The change of pH can 
change the state of ionization of the drug or the CD and lead the dissociation of the complex by 
decreasing its Kc. The way all these factors mentioned will influence the dissociation of the 
complex depends on the route of administration, the volume of distribution of the drug, the Kc 
and the complex concentrations of the drug, the CD and other competitive entities.
 [23] 
 
1.1.5 CD inclusion complexes in scCO2 
Nowadays, the combinatorial chemistry and high throughput screening, allow the discovery 
of new drugs with good pharmacological activities, but many of them have low solubility.
[26]
 The 
drug-CD complexes can bring substantial advantages like improvement of solubility, stability and 
bioavailability of drugs. The two main techniques to form complexes between CD and drugs in 
scCO2 are impregnation of CD matrixes with guest compounds and co-precipitation of CDs and 
guest molecules.
[27]
 
The impregnation of CD in scCO2 has been applied to generate inclusion compounds between 
CDs and therapeutic drugs. However, the formation of inclusion complexes depends on time and 
experiment conditions. The first step in the formation of the guest/host complex is the 
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solubilization of the drug in CO2 and the complexation of the solubilized drug with CD that 
would shift the equilibrium toward the dissolution of extra drug. A driving mechanism for the 
formation of CD inclusion complexes is the substitution of water of crystallization molecules in 
the CD cavity with hydrophobic guest. Since the removal of water of crystallization makes the 
hydrophobic cavity of the CD free to include other guest molecules, the extraction of the included 
water molecules in CO2 would favors the formation of the inclusion complex between the CD and 
the drug. The efficacy of CO2 in extracting water from the CD depends on the water solubility.
[27] 
 
The co-precipitation of CDs and guest compounds is another method that allows formation of 
complexes in CO2. The CD and the guest molecule are separately dissolved in different fluids and 
the two solutions were concomitantly contacted with the CO2 that expanded the two solvents, 
lowering their solvent power and causing the solutes precipitation. The solvents were removed 
from the systems by the CO2 and the product was collected in the form of dry powder.
 [27]
 
This is a technique to be explored since the CO2 constitute an environmentally sustainable 
technology and can be applied in several areas like biomedical and green chemistry.
 [27]
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1.2 Polymers 
1.2.1 scCO2 in polymer and impregnation process 
In this work, scCO2 was used as an alternative green media of polymerization, once it offers 
numerous advantages compared with other traditional methods that use solvents.
[28, 29]
 
Conventional production routes involve an excessive use of organic solvents, either as a reaction 
medium in the polymerization step or as a processing medium for shaping, extraction, 
impregnation, and viscosity reduction. In each of these steps, most of the effort of the process is 
put into solvent recovery.
[30]
 Therefore, it is highly desirable from environmental, safety and 
economical point of view, to develop alternative routes to reduce the use of solvents in 
polymerization processes.
 [28, 29, 31]
 
The scCO2 allows the preparations of hydrogels completely dry and free-flowing powders, 
with no solvent residues and with no need for intensive drying steps before processing.
[32]
 
Additionally, more attractive features are available: an easily accessible critical point (31.1 ºC and 
73.8 bar), abundance, non-flammable, non-toxic and relatively inexpensive.
[29, 31, 33]
 Due to the 
favorable practical physical and chemical properties of CO2, it is a solvent for monomers and a 
non-solvent for polymers, which facilitates the separation.
 [30] 
A supercritical fluid is defined as a substance for which the temperature and pressure are 
above their critical values and which has a density close to or higher than its critical density.
[29, 30] 
Above the critical temperature, the vapor-liquid coexistence line no longer exists. The 
supercritical fluids are versatile because their properties can be tuned from liquid to gas without 
crossing a phase boundary by simply changing the pressure or the temperature.
 [30]
  
In Figure 1.14, two projections of the phase behavior of carbon dioxide are shown. In the 
Figure 1.14, A, the pressure-temperature phase diagram, the boiling line, is observed, which 
separates the vapor and liquid regions and ends in the critical point.
 [29, 30, 34] 
At the critical point, 
the densities of the equilibrium liquid phase and the saturated vapor phases become equal, 
resulting in the formation of a single supercritical phase, which can be observed in the density-
pressure phase diagram (Figure 1.14, B).
[30]
 The density of scCO2 at its critical point is 450 kg/m
3
, 
however the transport properties of a supercritical fluid depend strongly of density, which in turn 
is sensitive to the pressure and temperature (Figure 1.14, B).
[34]
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Figure 1.14: Schematic phase diagram for pure CO2. A- The critical point at the critical 
temperature and the pressure marks the end of the vapor-liquid equilibrium line and the beginning of the 
supercritical fluid region. B - Density of CO2 as a function of pressure at different temperatures (solid lines) 
and at the vapor-liquid equilibrium line (dashed line).
[30]
 
Supercritical carbon dioxide is a non-toxic and non-flammable solvent with a low viscosity 
and high diffusion rate and no surface tension.
[28, 29]
 The disadvantage of CO2 is that only volatile 
or relatively non-polar compounds are soluble, 
[28, 29]
 however, the polarity can be turned by 
adding some amount of co-solvents and also several polymerizations approaches can be followed 
depending on the initial reaction phase behavior.
[29, 33]
 
 
1.2.2 Polymers in drug delivery 
Controlled drug delivery has emerged as a truly interdisciplinary science that aims to improve 
human health. The basic goal of controlled drug delivery systems is to deliver biologically active 
molecules at a desired rate and for a desired period, maintaining the drug levels in the body 
within the therapeutic window.
[35]
 
Most of the initially developed drug delivery systems were based on nondegradable 
polymers. However, the advent of synthetic biodegradable polymers coupled with the fact that 
macromolecules can be effectively delivered from these matrices, gave a new impetus to this 
branch of science.
[35]
 
Based on the nature of the carrier, controlled drug delivery systems can be broadly classified 
into liposomal, electromechanical and polymeric delivery systems. Liposomes belong to a family 
of vesicular structures based on lipid bilayers surrounding aqueous compartments. In the majority 
of cases, lipid complexes and liposomal pharmaceuticals provide less toxicity and better efficacy 
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than the active ingredient.
[36]
 Micro- and nano-electromechanical have many potentialities in drug 
release, like control the time and the doses administered. Micro-electromechanical has been used 
to construct microreservoirs, micropumps, nanoporous membranes, nanoparticles, valves, 
sensors, and other structures using biocompatible materials appropriate for drug administration. 
The focus of this section is polymeric drug delivery systems.
[35]
  
In polymeric drug delivery systems, the drugs are incorporated in a polymer matrix. The rate 
of release of drugs from such a system depends on a multitude of parameters such as nature of the 
polymer matrix, matrix geometry, properties of the drug, initial drug loading, and drug-matrix 
interaction.
[35]
 Therefore, controlled drug delivery can be used to achieve:
[37]
   
 Sustained constant concentration of therapeutically active compounds in the blood with 
minimum fluctuations;  
 Predictable and reproducible release rates over a long period time; 
 Protection of bioactive compounds having a very short half-life; 
 Elimination of side-effects waste of drug and frequent dosing; 
 Optimized therapy and better patient compliance 
 Solution to drug stability problems. 
 
Furthermore, the mechanisms for drug delivery systems can be classified into diffusion 
controlled systems, chemically controlled systems, and solvent-activated systems.
[38]
 
In diffusion systems, drugs diffuse through polymer: the polymer may undergo in subsequent 
biodegradation on exhaustion of the drug. Two types of diffusion-controlled devices have been 
used in drug delivery, these are reservoir devices and matrix devices.
[38]  
The reservoir systems are 
hollow devices in which an inner core of dissolved, suspended or neat drug is surrounded by a 
polymer membrane. In this device, the drug core is encapsulated in a polymeric membrane. Drug 
diffusion through the membrane is rate limiting and controls the overall drug release rate, and a 
saturated concentration of reservoir of the drug inside the reservoir is essential to maintain a 
constant concentration gradient across the membrane. The drug transport mechanism through the 
membrane is usually a solution-diffusion mechanism, and it occurs first by dissolution of the drug 
in the membrane in the one side, being followed by diffusion through the membrane and 
desorption in the other side.
[37, 38]
 In matrix systems, the drug is uniformly dissolved or dispersed. 
An inherent drawback of the matrix systems is their first-order release behavior with continuous 
decrease of release rate, which is due to the increasing diffusion path length and the decreasing 
area at the penetrating diffusion front (as the matrix release proceeds). The matrix device is easy 
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to formulate and gives higher initial release rate than a reservoir device and can be made to 
release at a nearly constant rate.
[37]
 
In chemically controlled drug delivery systems, the release of a pharmacologically active 
agent usually takes place in the aqueous environment by one or more of the following 
mechanism:
[37]
 
 Gradual biodegradation of a drug containing polymer system; 
 Biodegradation of unstable bonds by which the drug is coupled to the polymer 
system; 
 Diffusion of a drug from injectable and biodegradable microbeads. 
 
In biodegradable systems, the main advantages are elimination of the need for surgical 
removal, their small size and potential low cost. On the other hand, all biodegradable products as 
well as their metabolites must be non-toxic and non-carcinogenic, these requirements are not 
easily met and must be subject to careful scrutiny.
[37]
 
In pendent chain systems, the drug molecule is chemically bonded to a polymer backbone and 
the drug is released by hydrolytic or enzyme cleavage. The rate of drug release is controlled by 
the rate of hydrolysis. This approach provides an opportunity to target the drug to a particular cell 
type or tissue.
[37] 
 
1.2.2.1 Aspects to approve a new drug   
A number of factors that create hurdles for ultimate approval of the drug-loaded system in 
polymer medicine must be considered. Some of this factors are biocompatibility of the device, 
cytotoxicity, efficiency, inconvenience caused to patients, cost effectiveness, etc.
[37]
  
For the design of drug delivery systems with optimum performance in specific circumstances, 
the drug delivery systems has to confront the following challenges:
[37]
 
1. Improved efficacy; 
2. Targeted delivery and reduced side effects; 
3. Optimum performance; 
4. Interfacing and pacing with modern methodologies; 
5. Guarantees of safe environment; 
6. Ease of fabrication and application in reality. 
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The polymer hydrogels of different chemical architecture with novel physic-chemical 
properties have shown potential to find applications as promising drug carrying vehicles in 
several drug delivery platforms. Although their synthesis and in vivo study seems to be simple, 
from the point of view in vivo applications the polymers systems need to be judged with extreme 
care before they can be accepted ultimately for commercial applications.
[37] 
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1.3 CD complexes and pharmaceutical applications. 
The potential uses of CDs in pharmaceutical industry have been increasing in the last few 
decades and may explain their main application in drug delivery field. The CDs have the ability 
to form inclusion complexes with some drugs and improve some of their features like solubility, 
stability, safety and bioavailability.
[12, 39] 
 However the most desirable attribute for a drug carrier is 
the ability to deliver a drug to targeted site.
[40] 
 
CDs with hydrophobic liner cavities and hydrophilic outer surfaces are capable of interacting 
with a large variety of guest molecule to form noncovalent inclusion complexes. The cavity size 
of α-CD is insufficient for many drugs and γ-CD is expensive. β-CD has been widely used in the 
early stages of pharmaceutical studies because of its availability and cavity size, which gives a 
character suitable to interact with the widest range of drugs.
[12]
  
The effect of CDs on chemical stability of drugs is a useful property and has been extensively 
studied.
[41]
 CDs can be used to reduce or prevent gastrointestinal and ocular irritations, 
reduce/eliminate unpleasant smell or taste, prevent drug-drug or drug-additive interactions, or 
even to convert oils and liquid drugs into microcrystalline or amorphous powder.
[13, 39]
 Besides 
this the CDs can improve the stability of several labile drugs against dehydration, hydrolysis, 
oxidation and photodecomposition and thus increase the shelf life of drugs.
[12] 
  
1.3.1 Complexation and mechanism of drug release from CD complexes 
1.3.1.1 Aqueous Solution   
In aqueous solutions, CDs are able to form inclusion complexes with many drugs by taking 
up the drug molecule or some hydrophobic moiety of the molecule into the central cavity. No 
covalent bonds are formed or broken during the complex formation and the drug molecules in 
complex find rapid equilibrium (with free molecules in the solution).
[3, 39, 42]
 
 Phase-solubility analysis about the effect of complexing agents on the compound being 
solubilized is a traditional approach to determine not only the value of the stability constant but 
also to give insight into the stoichiometry of the equilibrium.
[3]
 The phase-solubility profiles as 
shown in Figure 1.15. In A systems, the apparent solubility of substrate increases as a function of 
CD concentration. Three subtypes have been defined: AL, when the complex is first order with 
respect to ligand and first or higher order with respect to substrate (drug); AP, systems indicate an 
isotherm wherein the curve deviates in a positive direction from linearity, i.e. the complex is first 
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order with respect to the substrate, but second or higher order with respect to the ligand and AN 
relationships indicate a negative deviation from linearity, i.e the CD proportionally less effective 
at higher concentrations. The A-type phase-solubility profiles indicate that water-soluble 
complexes are being formed with solubility higher than that of uncomplexed substrate.
 [3, 39, 42] 
Type B phase-solubility profiles indicate formation of complexes with a limited solubility in the 
aqueous complexation medium. BS-type isotherms indicate that the CD concentration increases, a 
soluble complex forms which increase the total solubility of the substrate. The BI systems are 
similar in form to the BS profiles except that the complexes being formed are so insoluble that 
they do not give rise to the initial ascending component of the isotherm.
[3, 39, 42] 
 
When the complexation of CD/drug is in aqueous solution two parameters are important, 
dilution and competitive displacement, because the complexation constant (K) and the lifetime of 
the complex are very importante for the drug release mechanism.
[13] 
 
1.3.1.2 Polymerization 
There are different classes of CD containing polymers. One of the types of polymers are 
those possessing a crosslinked structure (Figure 1.16, a), one of the first agents used for crosslink 
in CDs was epichlorohydrin (1-chloro-2,3-epoxypropane).
[11, 25]
 These were the initial CD-
containing polymers investigated for drug delivery applications. Other agents used for 
crosslinking are the diepoxides and diisocyanates. Another class of polymers are those containing 
CDs as pendent moieties in the polymers backbone (Figure 1.16, b), however this type of 
 
Figure 1.15: Graphical representations of A and B-type phase-solubility profiles. 
22 
 
polymers are prepared by functionalized CDs. In Table 1.2, some examples of pendent polymers 
are referred.
[15, 25]  
Table 1.2: Examples of CDs pendent polymers. 
Types of polymer CDs Preparation method 
Polyacrylic esters α and β Polymerization of vinyl CD derivatives 
Poly(allylamine)s β  and γ Grafting of CD to preformed polymer 
Polymethacrylates α, β and γ Polymerization of CD methacrylate monomers 
Polyester β Gratting of CD to preformed polymer 
 
A different type of CDs polymerized possesses a tubular structure, these polymers are then 
formed from the tubular configuration by crosslink between the CDs (Figure 1.16, c). The last 
class of polymers studied has a linear structure and contains CD as part of the backbone, as it can 
be seen in Figure 1.16, d.
[15, 25]
 
 
 
Figure 1.16: Classes of CDs-containing polymers.
[25]
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1.3.2 Pharmaceutical applications of drug-CD complexes 
Nowadays many drugs with CDs are available in the market with application in several areas 
of medicine, as shown in Table 1.3.
[1, 25, 43] 
Table 1.3: Approved and marketed drug-CD complexes.
 [1, 25, 43]
 
Drug Administration route Treatment Trade name Market 
α-CD     
Alprostadil (PGE1) Intravenous Vasodilation Prostavastin, Edex Europe, Japan, 
USA 
Cefotiam Hexetil HCl Oral Antibiotic Pansporin T Japan 
β-CD     
Dinoprostone (PGE2) Sublingual Labor induction Prostarmon E Japan 
Benexate Oral Antiulcer Ulgut, Lonmiel Japan 
Dexamethasone Dermal Analgesic Glymesason Japan 
Nicotine Sublingual Reducing the 
symptoms of 
absence 
Nicorette Europe 
Omeprazol Oral Antiulcer Omebeta Europe 
2-Hydroxypropyl-β-CD     
Hydrocortisone Buccal Anti-inflammatory Dexocort Europe 
Indomethacin Eye drops Anti-inflammatory Indocid Europe 
Random methylated β-
CD 
    
17β-Oestradiol Nasal spray Hormone therapy Aerodiol Europe 
Chloramphenicol Eye drops Antibiotic Clorocil Europe 
Sulphobutylether β-CD     
Voriconazole Intravenous Antimycotic Vfend Europe, USA 
2-Hydroxypropyl γ-CD     
Diclofenac sodium Eye drops Anti-inflammatory 
and analgesic 
Voltaren Europe 
24 
 
The first studies about the application of CDs in drug delivery experiments were with the 
prostaglandins (PGE). CDs complexes of PGE1 and PGE2 resulted in a significant increase in 
their solid-state stability, and a product designed along these lines was approved for the first time 
in Japonese market in 1976. Prostaglandins are used to relax smooth muscles and increase blood 
flow, and were initially developed in the therapeutic of peripheral circulatory disorders. Just after, 
in 1979, alprostadil alphadex (Prostavasin) was approved for the treatment of peripheral vascular 
complications and showed activity against chronic arterial occlusions and asteriosclerosis. CDs 
were applied to this compound in an effort to improve several properties, including safety and 
drug dissolution rate. These improved characteristics reduced gastrointestinal irritation, and 
allowed faster drug absorption and faster onset of analgesic effect.
[25] 
 
The implementation of structural changes in the CD allowed different pharmaceutical 
applications. For instance, the randomly methylated β-CD avoids a number of issues related to 
oral or transdermal administration and allows administration strategies like eye drop and nasal. 
The hydroxypropylated β-CD is available in registered oral, intravenous, buccal, rectal and 
ophthalmic products. The sulphobutyl ether β-CD has products like intravenous formulation of 
the antifungal agent voriconazole and an intramuscular dosage form for the antipsychotic agent 
ziprasidone.
[25]
 
These are only some examples about the available commercial applications of the CDs in 
pharmaceutical industry. There are many exciting possibilities for the future applications of CDs 
including new uses for existing derivatives, as well as the development of new derivatives.  
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2. Results Discussion  
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2.1 Objective 
From the point of view of pharmacotherapy optimization, drug release should be controlled in 
accordance to the therapeutic purpose and the pharmacological properties of active substances. 
There has been a growing interest in the development of a delivery system with rate- or time-
controlled oral administration, because appropriate drug release from dosage forms have critical 
importance for efficient therapeutics.
[44]
 
Cyclodextrins (CDs) are potential candidates for controlled drug delivery, once their cavities 
provide microenvironments where molecules can enter and form inclusion complexes. 
Supercritical CO2 (scCO2) is a sustainable alternative comparing to processes with organic 
solvents, and a very attractive medium for the preparation of these inclusion complexes.
[45]
  
This work aims to develop a new pH responsive CDs-hydrogel system in scCO2 with 
potential application on controlled drug delivery. The first part of this study consists on 
functionalization of β-CD with a group, such as activated double bonds that allow polymerization 
in scCO2. In order to prepare the desired β-CDs, two different approaches were used: 
regioeselective functionalization in the most reactive hydroxyls groups (C6-OH) and 
functionalization of a complete set of hydroxyls groups.
[3] 
The second part of this work envisages 
the polymerization of the functionalized β-CD in scCO2 and the investigation of the potential 
ability of polymer-CD to form inclusion complexes with the drug. In vitro experiments will be 
performed in order to evaluate the performance of the CDs-hydrogel system as drug release 
device at different pHs, 2.2 and 7.4, which simulate the gastric and colon experiments. The intent 
is to study the most appropriate application of these complexes.
1
   
In order to investigate the importance and role of CD cavity, three different β-CD derivates 
need to be prepared: the first involves the synthesis the of a monoacrylate-β-CD via the 6-
monotosyl-β-CD approach (Figure 2.1,1); the second consists of acrylation by a direct method 
(Figure 2.1, 2); and the third involves the exploration of a filled CD cavity to study its role  in the 
polymerization and interaction with the drug (Figure 2.1,3).  
                                                     
1
 The co-polymerization in scCO2 and the in vitro drug release experiments were performed with the 
collaboration of a PhD student (Mara Soares da Silva) from the group of Polymer Synthesis and Processing 
using Supercritical Carbon Dioxide (REQUIMTE). 
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Figure 2.1: Functionalized β-CDs (10, 11 and 12) which were synthesized for application on 
polymerization reaction, to study the formation of inclusion complexes with drugs. 
 
2.2 Synthesis of functionalized CDs 
The objective of synthesizing the compound 10 was to introduce a crosslink, a group with a 
double bond possessing an electron withdrawing group that allows subsequent polymerization in 
scCO2.  
In the first chapter, the main approaches described in literature (Chapter 1.1.3.1) to 
selectively functionalize CDs were presented. From the reported approaches, a route for a 
selective modification at C6-OH consists on to the  introduction of the tosyl group, a good leaving 
group and then substitution by  the desired functional group, by tosyl group displacement (Figure 
1.18).
[14]
  
To synthesize the 6-monotosyl-β-CD (5) three procedures were tested in order to achieve 
high yields of conversion. The first attempts of mono-tosylation were performed by treatment 
with p-toluenesulfonly imidazole,
[21]
 p-toluenosulfonic anhydride
[20]
 and p-toluenesulfonyl 
chloride
[19]
. The mechanisms of these reactions are very similar as noted in the Figure 2.2 and 
consist in a SN2 mechanism. In the first step, the base sodium hydroxide will remove the proton 
of the hydroxyl group forming an anion that will act as a nucleophile and attack the sulfur atom of 
the tosylation reagent, releasing: imidazole ion (a), tosyl ion (b) and chloride ion (c).
[19-21] 
The 
reactions a) and b) were quenched with ammonium chloride. The precipitate was a white powder 
that was filtered and washed with water.
[19-21] 
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a) Reaction of tosylation with toluenesulfonly imidazole. 
b) Reaction of tosylation with p-toluenesulfonic anhydride. 
c) Reaction of tosylation with p- toluenesulfonyl chloride.
 
Figure 2.2: Mechanisms of mono-tosylation reaction with different reagents to obtain 5. 
 
The yield of isolated and purified 5 varies depending on the tosylation reaction conditions 
(Table 2.1). Thus, a higher yield of 5 was obtained when p-TsCl was used as tosylation agent. 
 
Table 2.1: Yields of mono-tosylation reactions with different reagents. 
Reagents Yields 
p-Toluenesulfonly Imidazole 19% 
Toluenosulfonic Anhydride 10% 
p-Toluenesulfonyl Chloride 21% 
 
The NMR spectra of the 6-monotosyl-β-CD (5) were performed in DMSO-d6. In the 
1
H-NMR 
spectrum was possible to observe two types of resonance signals that indicated the presence of 
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this compound: the aromatic protons (7.4-7.7 ppm) and the methylic protons (2.5 ppm) of tosyl 
group (Figure 2.3).
[19-21]
 The NMR spectrum was in accordance with literature.
[19-21, 46]  
 
Figure 2.3: Structure of 5 and a representation of the chemical shift. 
The next step to obtain the desired products 6-mono-acryloyl/methacryloyl/-β-CD (10/13), 
consisted on the displacement of tosyl group by a proper nucleophile.
[47]
 The salt of methacrylic 
acid or acrylic acid was previously prepared by treatment with cesium hydroxide (Figure 2.4, 1
st
 
step).The salt formed was then added to a solution of 5, reacting as nucleophile and attacking the 
secondary carbon atom of 6-monotosyl-β-CD (5), releasing the tosyl group (Figure 2.4, 2nd 
step).
[48]
  The final product was obtained as a white solid, after several washing with ethyl ether 
and ethanol. The 6-mono-acryloyl-β-CD (10) was isolated with 79% yield and 6-mono-
methacryloyl-β-CD (13) was not possible to obtain completely pure. The overall yield to achieve 
compound 10 through compound 5 was 17%. This was the compound used for the studies of 
polymerization and interaction with a drug. 
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Figure 2.4: Mechanism of reaction to obtain 10 and 13. 
The NMR spectra of 10 and 13 were performed in D2O. In the case of 6-mono-methacryloyl-
β-CD (13) two signals were expected in the 1H-NMR around 5.6-6.3 ppm, due to the presence of 
the double bond and 2 ppm due to the methyl group (Figure 2.5).
[46, 48]
 
 
Figure 2.5: Structure of compounds 10 and 13 and a representation of the corresponding chemical shift. 
In spite of all efforts to remove the unreacted 6-monotosyl-β-CD (5), through washing and 
recrystallization, it was not possible to remove it completely. From the 
1
H-NMR spectrum of 6-
mono-acryloyl-β-CD (10) it was possible to observe three signals corresponding to resonances of 
the double bond protons between 5.5-6.4 ppm (Figure 2.5).
[19-21]
 In the 
13
C-NMR spectrum the 
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resonance signal correspondent to the carbon of carbonile carbon at 175.6 ppm and the signals of 
two carbons of the double bonds at 133.9 and 126.5 ppm were observed.
[46]
 From all 2D spectra 
only in the NOESY experience was possible to see a correlation between the anomeric (H1) 
protons and the double bond protons (H9,10) (Figure 2.6). 
 
Figure 2.6: NOESY HR-MAS NMR spectrum and correlations between the protons of β-CD and acryloyl 
group of 10. 
Due to the difficulty in preparing the 6-mono-acryloyl/methacryloyl-β-CD (10/13) 
completely pure, and in large amount needed for the scCO2 study, a less selective method was 
used to overcome this problem and have enough product to start the polymerization and drug 
delivery studies.
[49]
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In this second approach the β-CD (2) was slowly dissolved in pyridine to prevent the 
formation of a gel and subsequently the acryloly chloride in THF was added dropwise.
[50] 
The 
mechanism of this reaction is basically the attack of the oxygen atom to the carbonyl group with 
the release of chloride ion, which is a good leaving group. In Figure 2.7, is represented a 
mechanism for the acrylation of β-CD (11). 
 
Figure 2.7: Mechanism of preparation of acryloyl-β-CD. 
The product 11 was obtained with 94 % yield and presented a yellow/brown color. To 
characterize 11 by NMR DMSO-d6 and D2O were used as solvents. In the 
1
H-NMR spectra 
performed in D2O it was possible to observe a signal correspondent to the resonance of double 
bound protons between 5.9- 6.4 ppm (Figure 2.8).
[50]
   
 
Figure 2.8: Structure of 11 and a representation of the corresponding chemical shift.  
In the 
13
C-NMR spectrum it was possible to observe the resonance signal of the carbon of the 
carbonile group at 165.9 ppm and the carbons of the double bond between 132.0 and 128.0 
ppm.
[47, 50]  
However, in the 2D spectrum it was not possible to observe any correlation between 
the protons of the acryloyl group and protons of the β-CD. Moreover, the NMR study was 
realized in DMSO-d6 to analyze the signals of hydroxyls groups. Despite the fact of the 2D 
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experiments did not show evidence of a acryloly group covalently bonded connect to CD, in the 
1
H-NMR spectrum the integration of the number of protons for the hydroxyl groups (C2-OH, C3-
OH, C6-OH) suggests that the acryloly group is bounded to the C2-OH. The resonance signal of 
C2-OH and C3-OH appear in the same chemical shift while C6-OH appear at a higher field, thus 
integration suggest that the reaction occurred at C2-OH or C3-OH instead the most reactive 
hydroxyl group, C6-OH. However, due to the known higher reactivity of C2-OH it is proposed 
that the reaction occurred at this position.
[5] 
Figure 2.9, shows a proposed mechanism to explain 
the fact that acrylation reaction occurred inside the cavity of the β-CD. In MALDI-TOF 
spectrum,  the peak observed at 1268.6 m/z corresponds to monoacrylate-β-CD and in the IR 
spectrum a band at 1735 cm
-1
 confirm the presence of ester group.
[47]
 
Figure 2.9: Plausible mechanism proposed to the formation of 11. a) Reaction of pyridine with acryloyl 
chloride. b) Mechanism of reaction forming an inclusion complex with pyridine salt. 
The next synthesis envisaged the investigation of the importance of the free cavity of β-CD, 
in the process of polymerization and impregnation with a drug.  
To plan a modification in secondary hydroxyl group was necessary first to protect the 
primary hydroxyl groups, since these are the most reactive.
[14]
 Figure 2.10, shows the synthetic 
plan to obtain the desired product.
[18, 49-51]
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Figure 2.10: Synthetic plan to obtain 12.  
The requirements for the choice of the protecting group are their stability in the following 
reaction steps and the conditions to remove them. The deprotection conditions should not affect 
the groups introduced in the secondary hydroxyl groups. From all the protective groups and 
procedures described in literature, the TBDMS was the group of choice due to its easy removal 
by treatment with TBAF and also due to its stability under the proposed synthetic sequence.
[18] 
The synthesis of persilylated CD consisted on the use of TBDMSCl, that due to its bulkiness 
prevents the silylation at secondary hydroxyl groups.
[50]
 However, it was necessary to purify the 
resulting crude in a chromatography column with a gradient of solvents (MeOH:CH2Cl2). The 
persilylate-β-CD (4) was collected as a white solid and a yield of 81% was obtained.   
The mechanism of this reaction is depicted in Figure 2.11.  
 
Figure 2.11: Mechanism of reaction with TBDMSCl to afford 4. 
The NMR spectra were performed in CDCl3. The 
1
H-NMR spectrum showed two signals that 
indicate the presence of TBDMS group, the resonance signal at 0.04 ppm of the methyl groups 
and at 0.87 ppm correspondent to the protons of the tert-butyl groups (Figure 2.12). The MALDI-
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TOF spectrum confirmed that the sylilation occurred at all C6-OH positions by the presence of the 
peak at 1956.0 m/z.
[50]  
 
Figure 2.12: Structure of 4 and the corresponding chemical shift. 
The next step aimed to occupy the cavity of β-CD with benzyl groups, a large group that 
would fill the cavity and allow achievement of this study.
[51]
  
One of the procedures reported, involved the use of benzyl bromide. β-CD was dissolved in 
DMF and sodium hydride was added, a base to remove protons from the secondary hydroxyl 
group forming the corresponding anion. This anion will act as nucleophile and when benzyl 
bromide is added, the attack to the carbon atom that is bound to bromine occurs since bromine is 
a good leaving group (Figure 2.13).
 [51]
 The product was collect as a white solid in 43% yield. 
 
Figure 2.13: Mechanism of reaction with benzyl bromide to fill the cavity of β-CD and obtain 14. 
The NMR spectra were performed in CDCl3. The 
1
H-NMR spectrum shows the signal of 
correspondent to the resonance of the protons of TBDMS group which proves that this compound 
is stable under these reaction conditions. The 
1
H-NMR signals around the 7.0-7.3 ppm show that 
the benzyl groups are present in the cavity of β-CD (Figure 2.14).[51] The MALDI-TOF proves 
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that all the positions of secondary hydroxyl group are substituted by the presence of peak at 
3217.8 m/z.
[51]
 
 
Figure 2.14: Structure of 14 and a representation of the corresponding chemical shift. 
The third step of this synthetic route consisted on the deprotection of primary hydroxyl group, 
removing the TBDMS group. This reaction was performed in tetrahydrofuran (THF) with the 
TBAF reagent, a quaternary ammonium salt (Figure 2.15).
[18]
 
 
Figure 2.15: Mechanism of deprotection of primary hydroxyl group to obtain 15. 
The product 15 was obtained with a 94% yield and presented a yellow/brown color. The 
NMR spectra were performed in CDCl3, and in the 
1
H-NMR spectrum the absence of the signals 
correspondent to the resonance of methylic protons from the TBDMS groups indicated that the 
deprotection was successful (Figure 2.16).
[18, 46]
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Figure 2.16: Structure of compound 15 and representation of chemical shift. 
The last step consisted on the introduction of the cross-linking to polymerize the β-CD with 
filled cavity. The procedure for this step was the same used before for the product 11, by reaction 
with the acryloyl chloride (Figure 2.17).
[49]
  
 
 
Figure 2.17: Mechanism of reaction to obtain the final product (12) with acryloly chloride. 
The product was obtained with 65% yield. The 
1
H-NMR spectrum of compound 12 reveals 
the resonance signals of aromatic ring around 7.2-7.4 ppm (Figure 2.18). It was not possible to 
observe the resonance signals of the double bound protons due to the “ring –current effect”. This 
is an example of diamagnetic anisotropy that causes the large deshielding of benzene ring protons 
as well as protons near the aromatic ring.
[46]
 Due to the effect described, above the protons of 
double bond are deshielded, and their resonance signals are shifted to lower field appearing in the 
same field as the aromatic protons.
[46]
 Moreover, it was observed that the resonances of CD ring 
were also affected by the presence of the aromatic rings. This observation was already described 
in the literature.
[51]
 In MALDI-TOF the fragment at 2529.1 m/z corresponds to β-CD benzylated 
and acrylate in one position. Furthermore the IR spectrum showed the band at 1731 cm
-1
 
correspondent to the carbonyl of an ester group.
[46, 51]
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Figure 2.18: Structure of compound 12 and representation of chemical shift. 
In order to co-polymerize the compound 12 with functional monomers and study the interaction of the 
resulting polymer with a drug, a large amount was needed. With an overall yield of 21% it was necessary to 
reproduce the synthetic scheme many times to obtain the amount of product needed. 
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Table 2.2 presents the summary of the structural characterization (NMR, IR and ME) and 
yields of all compounds involved in synthesis of 10, 11 and 12. 
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Table 2. 2: Summary of structural characterization and yields of all compounds involved in 
synthesis of 10, 11 and 12. 
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2.3 Exploration of novel approach towards the 
functionalization of β-CD 
The selective modifications of CDs are a challenge, due the hydrophobic cavity and the large 
number of hydroxyl groups. Due to the hydrophobic cavity there is a tendency to form inclusion 
complexes with reagents of the synthetic scheme.
[14, 24]
 The hydroxyl groups C2-OH, C3-OH and 
C6-OH compete for the reagent and make the selective modification extremely difficult.
[14, 24]
 In 
literature, the main methods to selectively functionalize the CDs at C6-OH are via the use of 6-
monotosly-β-CD (5), but the synthesis of this compound has a very low yield.[5, 14] Due to the 
importance of developing new methods that allow the regioselective functionalization of β-CD 
(2) with a good yield, synthetic studies were performed using the acetyl group as an alternative to 
protect the primary hydroxyl groups (C6-OH). 
The first attempt consisted in the reproduction of a literature procedure using the acetyl 
chloride as acetylating agent (Figure 2.19).
[52]
 Two assays were performed, one with seven 
equivalents of base and reagent and other with ten equivalents. 
 
 
Figure 2.19: Mechanism of the acetylation reaction. 
 
In both experiments performed, two different reaction mixtures were obtained and analyzed 
by NMR. The NMR experiments of product obtained in the reaction with seven equivalents were 
performed in DMSO-d6. In the 
1
H-NMR spectrum it was possible to observe the resonance signal 
of methylic protons from the acetyl group at 2.16 ppm.
[46, 52]
 The MALDI-TOF spectrum revealed 
that the product obtained was a mixture of acetylated β-CD in one, two, three, four and five 
positions. However, the diacetylate β-CD was the major product (Table 2.3). The product 
obtained in the second reaction with ten equivalents, presented a 
1
H-NMR with the characteristic 
resonance signal at 2.16 ppm of the methylic protons, but the MALDI-TOF spectrum revealed 
that the product was acetylated mainly in three and four positions. Moreover, it was possible to 
observe a mixture of β-CDs acetylated until seven positions (Table 2.3). 
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Table 2.3: Number of equivalents of reagent used in the reactions of peracetylation and the products 
obtained. 
Nº equivalents of 
Acetyl Chloride 
Mass Spectrum  
(m/z) 
7 1241.7 (2 acetyl groups) 
10 1283.7 (3 acetyl groups) and 
1325.7 (4 acetyl groups) 
 
As the previous procedure did not result in the expected product and revealed to be a non-
selective approach, another approach was explored – use of benzotriazole as acetyl group transfer 
agent.
[53]
 The most used acylating agents are acetic anhydride, acetyl chloride, between others, 
which are small compounds, can easily access the CD cavity and thus  the regioselective 
functionalization of the β-CD is difficult.[16] The N-acylbenztriazole reagent is reported in the 
literature as a general reagent for N-acylation of amines and amides, the O-acylation of 
aldehydes, and the C-acylation of ketones and heteroaromatics, alksulfones, alkylcyanides and 
alkylazines (Figure 2.20).
[54-56]
 Acylation with the stable and crystalline N-acetylbenztriazole 
(17)
[56]
 has a great potential to selectively functionalize the β-CD, due to the size of the 
benzotriazole unit, the access to the cavity hydroxyls group C2-OH and C3-OH, will be more 
difficult.  
 
Figure 2.20: Examples of application of N-acylbenztriazole (Bt: benzotriazole)  
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The first step consisted on the synthesis of the N-acetylbenzotriazole (17). The reaction was 
run in DMF and diisopropylethylamine was added as base, subsequently the acetic anhydride was 
added and the desired product was obtained (Figure 2.21, a).
[53]
 The second step consisted on the 
reaction of the β-CD with 17 and the desired product 18 was obtained (Figure 2.21, b).[53] 
 
Figure 2.21: a) Synthesis of N-acetylbenztriazole (17), b) Mechanism of acetylation reaction with 
benzatriazole as transfer agent of the acetyl group.  
The first attempt to the peracetylation at C6-OH was performed with 14 equivalents of 17 and 
the reaction run during 24 h (18). In the 
1
H-NMR spectrum, in D2O, it was observed the signal 
correspondent to the resonance of methylic protons at 2.0 ppm.
[46, 53]
 The mass spectrum 
(MALDI-TOF) showed that the product is acetylated at eleven positions, but the major product 
has seven and eight acetyl groups. Another entry was performed with 2 equivalents of 17 with 
time reaction of 2 h in order to achieve mono-substitution at C6 and obtain the 6-monoacetly-β-
CD (19). Figure 2.22 is 
1
H-NMR spectrum of the compound obtained (19) and in the MALDI-
TOF spectrum it was possible to observe that the product is acetylated mostly in one and two 
positions. The yields were not calculated because the significant quantity of benzotriazole present 
in the final product.  
 
1
7 
1
8 
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Figure 2.22: Structure of compound 19 and representation of chemical shift..  
Table 2.4 summarizes the conditions and the products obtained by this method. 
Table 2.4: Conditions of the reactions with N-acylbenztriazole and products obtained 
Compounds 
 
Nº equivalents  
of 17 
Time of reaction  
(h) 
Mass Spectrum  
(m/z) 
18 14 24 h 1451.5 (9 acetyl groups), 
1535.5 (8 acetyl groups). 
19 2 2 h 1199.2 (1 acetyl group), 
1241.2 (2 acetlyl groups). 
 
This method needs to be optimized in two aspects: first, to improve reaction time and the 
number of equivalent of reagent; and second, improve the product isolation and separation from 
the benzotriazole ring. At the end of reaction the benzotriazole is released but difficult to isolate 
from the product due to similar solubility. One purification method tested was through a reverse 
phase column chromatography RP-18 with eluent H2O: MeOH (10:1), but the separation was not 
efficient, since the retention time of the compound and the benzotriazole in RP-18 is very similar. 
Another technique used was the process of ultrafiltration (UF). The UF is characterized by a 
membrane pore size between 2 nm and 0.05 µm and operating pressures between 1 and 10 bar.
[57, 
58]
 UF can be used to separate macromolecules (β-CD) from small molecules (benzotriazole), 
hence it is a method with potential to isolated the peracetylated-β-CD (18). Figure 2.23 shows a 
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scheme of UF and the cell used in the process.
[59]
 The membrane used had a pore size of 1000 
atomic mass units (daltons). By performing successive washes with H2O, compound 18 was 
retained in the membrane since it has a molecular weight of 1428.44 g/mol, while the 
benzotriazole crosses the membrane (119.12 g/mol). The number of washing operations was 
controlled by TLC, observing the presence of benzotriazole in UV lamp. However, the yield of 
this purification was low. In the future, in order to optimize the purification method, a membrane 
with a pore size of less than 1000 Da will be used to ensure that the peracetyl-β-CD does not 
cross the membrane and no losses will be observed.  
                 
Figure 2.23: a) Scheme of membrane for UF. 1-Ultrafiltrate, 2-UF equipment, 3-Pressure supply. b) UF 
equipment.
[59]
 
a) b) 
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2.4 Polymerization 
2.4.1 Synthesis of CD-MAA-PNIPAAm co-polymer in scCO2 
 The previously synthesized compounds 10, 11 and 12, shown in Figure 2.24, were co-
polymerized in scCO2 with the functional monomers methacrylic acid (MAA), a pH sensitive 
monomer and N-isopropylacrylamide (NIPAAm), a temperature sensitive monomer.
[60]
 
Ethyleneglycol dimethacrylate (EGDMA) was used as crosslinker and azobisisobutyronitrile 
(AIBN), as the radical initiator.
[61] 
In a typical polymerization 3.81 mmoles of a mixture of 
functional monomers the MAA and NIPAAm are in the proportion of 1:3,
[62]
 the compounds 10, 
11 and 12 are in 2.5% molar and the EGMA is in 1% molar, with respect to the total molar 
amount of functional monomers and crosslink (Figure 2.25). A co-polymer with 8.8 % molar of 
compound 11 was also prepared in order to study the effect of the CD content in the co-polymer.  
The AIBN is in 1 wt%, with respect to the total mass of MAA, NIPAAm and EGDMA.  
 
Figure 2.24: Synthesized β-CDs that were co-polymerized in scCO2. 
 
 
Figure 2.25: Scheme of the co-polymerization reaction. 
The co-polymerization reactions were performed in a high pressure apparatus already existing 
in the host laboratory as described elsewhere
[28]
 and schematically presented in Figure 2.26. 
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Figure 2.26: Schematic representation of equipment used in polymerization reaction and impregnation. 1- 
Nitrogen cylinder; 2-Gas regulator; 3-Rupture disc; 4- High-pressure manometer; 5- Check-valve; 6- Line 
filter; 7-Water bath; 8-Immersible stirrer; 9-High pressure cell; 10- Platinum resistance RTD probe; 11-
Temperature controller; 12-Vent; 13- Pneumatic CO2 compressor; 14- CO2 cylinder; M1,M2- bourbon 
manometers; wp-water recirculation pump; V1 to V7- HIP valves. 
The polymerization reaction was performed in scCO2 in a stainless steel high-pressure cell at 
65 ºC and 24 MPa, for 24 h.
[61]
 The cell is equipped with two aligned sapphire windows, which 
allow full observation of the reaction mixture during the polymerization and assure that a 
homogeneous phase is attained at the beginning of the reaction. At the end of the reaction the 
system is quickly depressurized, and the polymer is collected inside the cell. 
 
2.4.2 Characterization of polymers 
The synthesized polymers were obtained as white, dry, free flowing powders at the end of the 
reaction as it can be seen in Figure 2.27.  
 
Figure 2.27: Appearance of the co-polymer obtained.  
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Figure 2.28 shows scanning electron microscope (SEM) images of compound 10 (A) and of 
the synthesized co-polymers (B, C, and D). As it can be seen in Figure 2.28A the compound 10 
appears as irregularly shaped crystals. The co-polymers of respective compounds 10 (B), 11 (C) 
and 12 (D) are very homogeneous in terms of particle size, with slightly agglomerated discrete 
particles sizing less than 1 µm. It seems that the nature of the CD in the co-polymer does not 
interfere much in the morphology of the co-polymers. Another type of structural characterization 
that could have been made was the measurement of porosity of the co-polymers, since the 
molecular-sized pores have a great influence in the capacity of absorption and liberation of a 
drug. However, this was not possible in this thesis due to the little amount of polymer samples 
available.  
 
Figure 2.28: SEM images of: A - compound 10; B - NIPAAm-MAA-EGDMA co-polymer 10; C- 
NIPAAm-MAA-EGDMA co-polymer 11; D - NIPAAm-MAA-EGDMA co-polymer 12. 
The major problem faced in the structural characterization of the synthesized co-polymers by 
NMR was their low solubility in organic solvents and water, as expected due to crosslinking. 
Several studies of solubility in mixed solvents were realized and only a small amount was 
dissolved being in the limits of detection of NMR in solution. An alternative was to characterize 
the polymers by High Resolution Magnetic Angle Spinning (HR-MAS), a well developed NMR 
technique that offers many possibilities to further investigate samples between the liquid and the 
solid state.
[63]
 The structural framework required an intensive study of the appropriate parameters 
(pulse sequence, spectral window, acquisition time, mixing time) to allow structural assignment 
of the β-CD co-polymers.  
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In the 
1
H HR-MAS NMR of co-polymer of compound 10 was not possible to observe the 
resonance signals of double bond protons between 5.5-6.4 ppm, which means that the 
polymerization was initiated there and all the double bond reacted. In 2D spectra only the 
NOESY spectrum gives relevant information, since it is possible to observe interaction between 
the protons of polymer and the protons H5 and H3 of the cavity of β-CD (Figure 2.29). The 
polymer in NOESY spectrum does not show corrections with the protons outside the cavity of β-
CD, probably due to distances higher than 6 Å, which is the limit of detection of interaction in 
NOESY experiment. 
 
Figure 2.29: NOESY HR-MAS NMR spectrum and representation of co-polymer of compound 10.  
The co-polymer of compound 11 presents a 
1
H HR-MAS NMR where signals of double bond  
protons are observed, meaning that not all the acryloyl group led to a starting point for co-
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polymerization. In the NOESY HR-MAS NMR spectrum interaction between the polymer chain 
and the proton H3 or H5 of the β-CD cavity can be observed.  
In 
1
H HR-MAS NMR spectrum of the polymer of compound 12, the due to the presence of 
multiple aromatic rings, the signals of aromatic protons do not allow the observation the signals 
of double bound protons. The interaction between the protons of polymer and the CH2 of benzyl 
group, in the NOESY HR-MAS NMR spectrum confirms that the polymer crosses the β-CD 
cavity. 
In literature three types of β-CD polymers are described: catenanes - molecules that contain 
two or more interlocked ring (Figure 2.30, A); rotaxanes which are macrocycles trapped on the 
ends with compounds larger than the internal diameter of the ring, to prevent the disassociation of 
the components (Figure 2.30, B); and the pseudorotaxanes that are similar to the rotaxanes but 
with or without groups at the end (Figure 2.30, C).
[15, 64, 65]
 In the characterization of co-polymers 
by HR-MAS NMR it was observed the interaction between the polymer and the protons of the 
cavity of β-CD, which means that our co-polymers can be characterized as pseudo-polyrotaxanes.  
 
 
Figure 2.30: Types of β-CD polymer: A-catenanes, B-rotaxanes and C-pseudorotaxanes.[64] 
Another technique of structural characterization used was the X-Ray Diffraction (XRD). 
Figure 2.31 shows XRD of the synthesized co-polymer with and without the derivate of β-CD 
and the compound 10. As it can be seen and as expected in a polymerization in scCO2, the 
polymer is completely amorphous. The compound 10 shows a quite crystalline pattern. This 
compound was dissolved in scCO2 and precipitated in order to be compared with the polymers 
processed in scCO2. The pattern suggests that compound 10 maintained a crystalline structure 
even after being processed in scCO2. The co-polymer from compound 10 shows a quite 
amorphous structure. However, it presents two sharp peaks at two predominant diffraction peaks 
located at 22º and 31º of 2θ. This suggests that some polymer parts are crystalline, probably due 
to the presence of derivate 10, since these peaks are also in the compound 10 pattern. 
Nevertheless, these peaks show a slight shift which suggest that a new entity was formed (in this 
case the co-polymer) and it is not a physical mixture. 
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Figure 2.31: XRD of P(NIPPAm-MAA) (blue), P(NIPAAm-MAA-10) co-polymer (orange) and compound 
10 (gray). 
Figure 2.32 shows the XRD of the synthesized polymer with and without the derivate of β-
CD and the compound 11. As it can be seen this polymer is also completely amorphous. The 
pattern of the 11 is typical of a crystalline structure. The resultant co-polymer also shows an 
amorphous structure. The pattern shows some low intensity peaks which are in accordance with 
the existence of crystalline parts of the co-polymer. The pattern of the polymer does not 
correspond to the sum of the patterns of the 11 and the polymer without β-CD, meaning that the 
co-polymer 11 it is a new entity. 
 
Figure 2.32: XRD of P(NIPPAm-MAA) (blue), P(NIPAAm-MAA-11) co-polymer (green) and compound 
11 (gray). 
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Swelling tests were performed to the synthesized co-polymers at different pHs (Figure 2.33). 
The polymer showing higher swelling is the one without β-CD. These results suggest that the 
introduction of the CDs in the co-polymer can decrease the flexibility of the polymeric chains in 
solution. A possible explanation is an increase of the crosslink degree or the interference of the β-
CD in the interchain interactions of the pH responsive backbones of the polymer. From the 
polymers containing β-CD the co-polymer prepared using the β-CD with the acrylated 
functionalization inside the cavity, compound 11, shows a slightly higher swelling. 
 
 
Figure 2.33: Swelling of co-polymers at two different pHs 2.2 and 7.4. P(NIPAAm-MAA) (blue), 
P(NIPAAm-MAA-10) co-polymer (orange), P(NIPAAm-MAA-11) co-polymer (green) and (NIPAAm-
MAA-12) (purple). 
The pH responsive character of the polymers can be easily seen in Figure 2.34, where the 
water uptake and swelling is quite visible. 
 
Figure 2.34: Test of swelling. A-(pH2.2); B-(pH7.4). 
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After co-polymerization of the derivatives of β-CD (10, 11 and 12) and in order to test the 
polymeric materials as drug delivery devices, the co-polymers were impregnated with a drug 
using a scCO2-assisted method. Metronidazole (Figure 2.35) is an antibacterial drug and it is used 
in combination with other antibiotics.
[66]
 It was chosen drug because its solubility in solution is 
independent on pH.
[67] 
This is important because the release profiles obtained will be only 
dependent on the co-polymer itself and not on the drug solubility at the different studied pHs. 
Additionally this drug is soluble in scCO2.
[68]
 
 
 
 
 
 
  
Figure 2.35: Structure of metronidazole. 
The impregnation of metronidazole was undertaken in a cell similar to the one used in the 
polymerization, with an inner porous support which divides the cell in two compartments, as it 
can be seen through the sapphire window of the cell shown in Figure 2.36. This prevents physical 
contact between the drug and the co-polymers that could interfere in the impregnation process.  
 
 
Figure 2.36: High-pressure cell used for impregnation. 
The drug was placed in the downer compartment, under the porous support with a magnetic 
stirring bar, and in quantity enough to obtain a saturated solution at 65ºC and 24 MPa. The co-
polymers were loaded into cellulose membranes which were placed in the upper compartment of 
the cell. After 24 h, the system was quickly depressurized.  
After impregnation with metronidazole, in vitro drug release experiments were performed, in 
order to evaluate the performance of the cyclodextrin-hydrogel system as drug release device at 
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pH 2.2, to simulate the gastric conditions and at pH 7.4 to reproduce the colon environment.  The 
co-polymers were transferred to porous membranes and added to a buffer solution (pH 2.2 and 
7.4) at controlled temperature 37ºC. Aliquots were withdrawn at time intervals and the same 
volume of fresh medium was added to the solution. Quantification was performed by making a 
calibration curve in a spectrophotometer (Perkin Elmer, Lambda 25) at 265 nm (pH 2.2) and 318 
nm (pH 7.4) and the total mass released was determined considering the aliquots and the dilution 
produced by addition of fresh buffer solution.  
Table 2.5 summarizes the impregnation loading obtained for each polymer using the 
supercritical assisted method. 
Table 2.5: Polymer loading during scCO2-assisted impregnation with Metronidazole. 
Entries Compounds Metronidazole loaded 
(mg/g)* 
1 Poly 7.85 
2 Co-polymer 10 (2.5%) 6.69 
3 Co-polymer 11 (2.5%) 11.30 
4 Co-polymer 12 (2.5%) 3.54 
5 Co-polymer 11 (8.8%) 21.04 
               * wt Metronidazole (mg) with respect to the co-polymer sample (g). 
 
The impregnation in scCO2 depends mainly in the high scCO2 diffusivity within the polymer 
structure, swelling and drug solubility, and has two contributions: the impregnation within the 
polymeric chains and into the β-CDs cavities.[69] As it can be seen by comparing entries 3 and 5 
of Table 2.5 corresponding to the same co-polymer but with different percentages of β-CD. The 
increase of the β-CD content leads to a very significant increase of the loaded drug. This could be 
explained by the accessibility of part of the β-CD cavities since probably not all cavities have 
polymeric chains passing through. Also the polymer that has the wider opening of the β-CD 
obstructed by voluminous groups (co-polymer 12) presents the lowest metronidazole loading, 
even less than the polymer without CDs. This fact could be explained by the inaccessibility of the 
cavities as well as to different intermolecular interaction within the polymer due to the lack of 
hydroxyl groups available at the CD to establish hydrogen bonding. This can lead to different 
polymer conformations and also to different porosities that influence the impregnation. 
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These differences are difficult to explain since one may expect that similar drug loads would 
be obtained due to the high diffusivity of CO2 within similar polymeric matrixes. However as it 
was already discussed above, these polymers can have different porosities, which can greatly 
interfere with the accessibility of the drug into the copolymer. Additionally the different swellings 
of the matrixes in scCO2 have to be taken into account, which study was not in the scope of this 
thesis but is known to greatly influence the impregnation in scCO2. 
After the impregnation the pressure is rapidly decreased leading to a sudden change in the 
medium density and in all the properties density-dependent as solubility, thus the drug stays 
entrapped in the polymeric net whereas the CO2 is released as a gas. 
Figure 2.37 presents the in vitro drug release of metronidazole from the different synthesized 
co-polymers for a period of 5 h at pH 2.2 (A) and pH 7.4 (B).  Figure 2.37A shows the percentage 
of drug released at pH 2.2 where it is possible to see that polymers of 10 and 12 have similar 
behavior to the polymer without β-CD, releasing almost all the drug in the first hour. Polymer 11 
shows a more controlled release, since at the end of the first hour only 60% of the metronidazole 
was released and after 3 h the maximum was achieved, although not reaching a complete release. 
Figure 2.37B represents the behavior of the co-polymers at pH 7.4 where it is possible to observe 
that polymer of 11 was the one that released the drug more quickly, 80% after 30 min and 100% 
after 1 h.  Polymers 10 and 12 released the maximum metronidazole in approximately 2 h, while 
polymer 10 releases the drug in a slightly more controlled way: after 1 h only 70% of the 
metronidazole was release, and after 5 h 85-90% of the drug was liberated. 
56 
 
 
Figure 2.37: Drug release from the synthesized P(NIPAAm-MAA) (blue), P(NIPAAm-MAA-10) co-
polymer (orange), P(NIPAAm-MAA-11) co-polymer (green) and (NIPAAm-MAA-12) (purple) at pH 2.2 
(A) and pH 7.4 (B). 
From these results it is possible to conclude that the polymer synthesized with compound 11, 
is the only one that shows some of the expected pH responsiveness trend. At pH 2.2 the release is 
slower and at pH 7.4 presents the highest release of all the polymers. This behavior suggests that 
probably the polymeric MAA backbone (pH sensitive) of the polymer is available to interact with 
the medium, inducing changes in the polymer conformation. The co-polymer 11 showed a higher 
swelling than the other polymers at pH 7.4 meaning that at this pH condition the polymeric 
matrix is more hydrated, thus the drug diffusion from the matrix is likely to be slightly more 
rapid. 
In the swelling test it was possible to observe that the presence of β-CD decreases the 
swelling of the co-polymer and that different swellings are obtained at the different pHs, thus 
being sensitive to the pH.  
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Since the co-polymer of compound 11 shows the better swelling, was the co-polymer that 
impregnated more drug and have a significant response at different pHs, this was the co-polymer 
chosen to repeat the polymerization reaction with a higher percentage of compound 11, 8.8 % 
(molar). Figure 2.38 compares the release of metronidazole from the polymers with 2.5% and 
8.8% of compound 11. At pH 2.2 the polymers with 2.5% and 8.8% of 11 have a similar drug 
release profiles (Figure 2.38, A) not achieving 100% of metronidazole release.  At pH 7.4 the 
polymer with 2.5% of 11, released 75% of the drug after one hour achieving its maximum in 4 h 
while polymer with 8.8% of 11 presented a very different behavior (Figure 2.38, B). The polymer 
with 8,8% of 11 has a significant controlled drug release, only 30% of the metronidazole was 
released after one hour, 60% were released after three hours and the maximum release is achieve 
only in nine hours. According to the observed result with 2.5% β-CD, this result was unexpected. 
This strongly suggests that when the percentage of β-CD is increased more β-CDs are available, 
free cavities and external hydroxyl groups, within the polymer. 
Moreover, as it can be seen in Figure 2.39 the drug release is more sustained at the highest 
pH, achieving the maximum release in 8 h while at pH 2.2 this maximum is achieved around 3 h. 
This behavior can also be explained by the pKa value of the β-CD (12.2)[15] and of metronidazole 
(16.0)
[70, 71]
. At pH 2.2 both the CD and the drug are totally protonated. At pH 7.4 both the CD 
and the drug are neutral thus are available to establish hydrogen bonding interactions between 
them. Therefore the polymer has the capacity to establish hydrogen bonding with the drug at the 
highest pH, and thus leads to a more sustained release of the drug. This controlled release at pH 
7.4 suggests a new application for this material as parenteral rectal delivery device. 
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Figure 2.38: Drug release from the synthesized P(NIPPAm-MAA) (blue), P(NIPAAm-MAA-11) co-
polymer  with 2.5% (green) and P(NIPAAm-MAA-11) co-polymer with 8.8% (gray) at pH 2.2 (A) and pH 
7.4 (B). 
 
Figure 2.39: Drug release from the synthesized P(NIPAAm-MAA-11) co-polymer with 8.8% at pH 2.2 
(blue) and P(NIPAAm-MAA-11) co-polymer with 8.8% at pH 7.4 (gray).  
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Figure 2.40 shows one of the co-polymers in water. As it can be seen, the polymer shows a 
significant temperature responsive behavior, although it would be expected that the co-polymer 
with the ratio 25:75 (MAA:NIPPAm) would exhibit a strong pH responsiveness but would not be 
temperature dependent.
[62]
 Neverthless, the polymers reported in literature were synthesized by 
conventional methods. In this case different interactions are established during polymerization 
and consequently different polymer conformations can be obtained which obviously can lead to 
different polymer-solvent interactions during the drug release experiments. From Figure 2.40 it is 
obvious that the co-polymers show a LCST (lower critical solution temperature), which was not 
determined in this work. It is clear that at room temperature the polymeric chains are completely 
free to establish hydrogen bonding with water, although it does not dissolve due to crosslinking. 
At higher temperature (Fig 2.40, B at 45ºC) the co-polymer chains are collapsed due to the 
disruption of these bonds, so the polymer shrinks.  
 
 
Figure 2.40: Temperature test of co-polymers A- 23ºC, B- 45ºC. 
In the swelling test it was observed that the presence of β-CD units decreases the swelling of 
the co-polymer and that this is sensitive to the pH. The metronidazole was impregnated in the co-
polymers and the one that had more capacity to permeate the drug was the co-polymer of 11 (2-
monoacryloyl-β-CD, 2.5%). This result is in accordance with the fact that this polymer presented 
a better swelling.  
  
A B 
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2.5 Final Conclusions 
The purpose of this study was to synthesize polymerizable CDs in order to develop new CD-
hydrogel systems in scCO2 for pH-responsive drug delivery.  
The first part of this thesis consisted on the synthesis of polymerizable β-CD, by 
functionalization of β-CD with a group that allows the polymerization (activated double bonds). 
This was the first challenge of this work, since the reactions performed had low yield, and were 
difficult to reproduce in a large scale. Moreover, for the co-polymerization reactions using 
supercritical fluid technology, high amounts of these compounds were needed. Thus, three 
functionalized β-CDs were prepared by different synthetic sequences: 6-monoacryloyl-β-CD 
(10), 2-monoacryloyl-β-CD (11) and 6-monoacryloly-heptakis-(2,3-di-O-benzyl)-β-CD (12). The 
6-monoacryloyl-β-CD (10) was obtained via 6-monotosyl-β-CD, while the 2-monoacryloyl-β-CD 
(11) was prepared by direct acrylation using acryloyl chloride. For the 6-monoacryloly-heptakis-
(2,3-di-O-benzyl)-β-CD, a longer synthetic sequence was needed, the primary hydroxyl groups 
was first protected by silylation and the secondary hydroxyl groups was then benzylated. 
Removal of the silyl groups and subsequent direct acrylation afforded the final functionalized β-
CD. The 6-monoacryloyl-β-CD (10) was obtained with a yield of 17 %, while the 2-
monoacryloyl-β-CD (11) with 94 % and the 6-monoacryloly-heptakis-(2,3-di-O-benzyl)-β-CD 
(12) with 21 %. Compounds structures were confirmed by NMR, IR and MS by MALDI-TOF 
technique.  
The second part of this work consisted in the synthesized CD-co-polymers for a 
pharmaceutical targeted application. The polymerizable β-CD derivatives previously prepared 
were co-polymerized with functional monomers using a clean technology, supercritical fluid 
technology. The characterization of these materials were difficult, mainly due to the co-polymers 
have low solubility as a consequence of crosslinking. Through HR-MAS NMR, structural 
information about the co-polymers, were obtained being observed that polymeric chains interact 
with the β-CD cavity, what strongly suggest the formation of supramolecular structures: pseudo-
polyrotaxanes.  
Moreover, supercritical fluid technology was found to be a suitable “green” process to 
impregnate polymeric materials with a drug. The impregnation degree was affected by the 
percentage of β-CD units present in the polymer and by the different positions of the β-CD where 
polymerization occurred (related to the position in which acrylation took place in the CD). 
From the studied co-polymers with β-CD derivates, co-polymer 11 demonstrated a higher 
capacity to impregnate the drug. The results showed that co-polymer of compound 11 (2.5 %) had 
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a better controlled drug release, at pH 2.2, when compared to the other co-polymers. Increasing 
the percentage of compound 11 (8.8 %) in the co-polymer led to improved control of drug 
release, at pH 7.4. This result suggests that the amount of β-CD present in the co-polymer might 
be crucial for the co-polymer performance. Co-polymer 12, despite the steric hindered cavity, was 
still capable to impregnate some drug. The results indicate that the β-CD cavity might not be the 
only factor influencing the interaction between β-CD and the drug. 
The materials produced showed some pH-responsiveness, being quite promising in the 
development of co-polymers for controlled drug administration. The results obtained indicate that 
co-polymer with 2.5 % of compound 11 would be more suitable for oral administration, while the 
co-polymer with 8.8 % of compound 11 might be preferred for parenteral administration. 
The research area covered in this thesis is quite vast, ranging from organic chemistry to 
chemical engineering and material’s characterization. The co-polymerization using supercritical 
fluid technology involved a completely different type of experimental approach. In addition, the 
final characterization of the polymers was complex and difficult, as the co-polymers were 
crosslinked and built with four monomers, influencing the final properties of the co-polymer. The 
homogeneity of the assembling during polymerization also affected these properties.  
The work developed in this Master thesis is a good starting point for the study of these 
complex supramacromolecular structured materials. Such materials have huge potential in the 
pharmaceutical and biomedical areas, where the supercritical fluid technology can have a real 
impact in the materials purity and in the processes sustainability. 
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3. Experimental Part 
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3.1 Preamble  
The experimental part of this work involves the applications of some general procedures that 
will be described next: 
 Usual work-up implies drying the water- or brine-washed organic extracts over 
anhydrous sodium sulfate or magnesium sulfate, followed by filtration and 
evaporation of the solvent from the filtrate under reduced pressure. Anhydrous 
solvents were dried as described
[72]
 and freshly distilled. 
 Thin-layer chromatography was performed on Merck silica gel 60 F254 plates and 
PTLC on 0.5 mm thick plates. Column chromatography was carried out on Merck 
silica gel 60 (70–230 mesh).  
 IR spectra were run on a FT Perkin–Elmer 683 instrument, with absorption 
frequencies expressed in reciprocal centimeters. 
 Ultraviolet-visible (UV-Vis) spectroscopy spectra were traced in spectrophotometer 
Perkin Elmer, Lambda 25. 
 High resolution mass spectra (MS) were recorded on Mass Spectrometry Unit, 
University of Santiago of Compostela and Analyses Services MALFI-TOF-MS of the 
Chemistry Department, Faculty of Science and Technology, New University of 
Lisbon. In the description of the spectra data are presented in the following order: 
load mass ratio (m/z) assignment of a molecular fragment. 
 In nuclear magnetic resonance spectroscopy (NMR) the equipment used to obtain the 
spectra 
1
H-NMR, 
13
C-NMR was the Brucker CXP 300 (400 MHz and 100 MHz 
respectively). 
 In high resolution magnetic angle spinning (HR-MAS) the equipment used to obtain 
spectra 
1
H HR-MAS and 
13
C HR-MAS was the Bruker Avance III (400 MHz and 100 
MHz) respectively, with 4 mm triple resonance HR-MAS probe head at ambient 
temperature.
2
 Samples were spun at the magic angle at a rate of 4.0 kHz in a rotor of 
4 mm of zirconium with 50 µl of capacity, and all the spectra acquired under fiel-
frequency locked conditions using that probe channel with the spectrometer’s lock 
hardware. Spectra were processed using Brucker Topspin 2.1. The 
1
H HR-MAS 
                                                     
2 The NMR spectrometers are part of the National NMR Network and were purchased in the framework of the 
National Programme for Scientific Re-equipment, contract REDE/1517/RMN/2005, with funds from POCI 2010 
(FEDER) and Fundação para a Ciência e a Tecnologia. 
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NMR were acquired between 4 and 6 seconds in 16 transients and a spectral width of 
ca between 5300 and 6200 Hz. The 
13
C HR-MAS NMR were acquired in 1.36 
seconds in 16 transients and spectral with of 24000 Hz. NOESY experiments were 
acquired with 200 miliseconds mixing time in 16 transients with a relaxation delay of 
2.0 seconds and a spectral width of  ca 4100 Hz, in a total of 2 K data points in F2 
and 256 data point in F1.  In the description of the spectra data are presented in the 
following order: deuterated solvent, chemical shift (δ, in ppm), multiplicity of the 
signal (s – singlet, d- duplet, dd-  duplet dupleto, m- multiplet), coupling constant (J 
in Hertz), identification of carbon and number of protons.  
 X-Ray Diffraction (XRD): Diffractometers Phillips (2) (PW-1730/10 e X’Pert Pro) 
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3.2 Synthesis  
3.2.1  Synthesis of compound 10 (6-monoacryloyl-β-CD) 
 
Figure 3.1:  Synthetic scheme to obtain products 10 and 13. 
 
3.2.1.1  Synthesis of 6-Monotosyl-β-cyclodextrin (5) 
Method A 
[21]
  
β-CD (2 g, 1.76 mmol) was dissolved in hot water at 80 ºC, then cooled down to room 
temperature under vigorous stirring. p-Toluenesulfonyl imidazole (0.78 g, 3.51 mmol, 2 equiv.) 
was added as finely grounded powder, and the suspension was stirred for 2 hours (h). Sodium 
hydroxide (0.90 g, 37.5 mmol) was dissolved in water (2.5 mL) and the solution was added to the 
reaction mixture over a period of 20 minutes (min). After stirring for another 10 min, the mixture 
was filtered through a frit funnel. The reaction was quenched with ammonium chloride (2.41 g), 
and the solution was concentrated to about half of its volume. After stirring at 0 ºC for 1 h, the 
precipitate was filtered, washed with water (2.5 mL), acetone (2.5 mL), and then dried in vacuum. 
η=19%.  
 
Method B
 [19]
 
β-CD (2 g, 1.76 mmol) was suspended in water (17 mL), and NaOH (0.22 g, 5.47 mmol)  in 
water (6 mL) was added dropwise. The suspension became homogeneous and slightly yellow 
before the addition was complete. p-Toluenesulfonyl chloride (0.34 g, 1.78 mmol) in acetonitrile 
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(1 mL) was added dropwise, and a white precipitate was formed. After 2 h stirring at room 
temperature the precipitate was removed by suction filtration and the filtrate refrigerated 
overnight at 4 ºC. The resulting white precipitate was recovered by suction filtration and dried in 
vacuum. η=10 %.  
 
Method C
 [20]
 
A suspension of β-CD (2 g, 1.81 mmol) and p-toluenesulfonic anhydride (0.88 g, 2.70 mmol), 
in water (44 mL) was stirred at room temperature for 2 h. An aqueous solution of NaOH (0.9 g, 9 
mL) was added, and after 10 min unreacted p-toluenesulfonic anhydride was removed by 
filtration in vacuum. NH4Cl (1.26 g, 23.6 mmol) was added to the filtrate affording 6-monotosyl-
β-CD as a precipitate that was cooled at 4 ºC overnight. The product was washed with cold water 
(to remove the salts), then with acetone. The product was obtained as a fine white powder after 
drying under high vacuum. Compound 5: η=21%. 1H-NMR (δppm, DMSO-d6): 7.49 (d, J= 8 Hz, 
H7,7’, 2H); 7.13 (d, J= 8 Hz, Ar-H, H8,8’, 2H); 5.69 (s, OH2,3, 14H); 4.84 (d, J=4 Hz, H1, 7H); 4.48 
(s, OH6, 5H); 3.67 (m, H6,3, 21H); 3.56 (d, J=12 Hz, H5, 7H); 3.39 (s, H4, 7H); 3.29 (s, H2, 7H), 
2.30 (s, H9, 3H). 
13
C-NMR (δppm, DMSO-d6): 128.6 (C8,8’), 126.0 (C7,7’), 102.4 (C1), 82.0 (C4), 
73.6 (C3), 72.9 (C2), 72.5 (C5), 60.4 (C6), 21.3 (C9).
 [19]
   (Appendix 1) 
 
3.2.1.2 6-Mono-acryloyl/methacryloyl-β-CD (10/13) [48] 
Methacrylic acid or acrylic acid (4.29 mmol), was added dropwise to an aqueous solution of 
CsOH (50%, 0.73 mL, 4.29 mmol), at room temperature. The mixture was stirred for 30 min, and 
concentrated under reduced pressure. The resulting salt was dissolved in dry DMF (5 mL) and 6-
monotosyl-β-CD (0.56 g, 0.43 mmol) was added. The resulting mixture was heated at 90 ºC for 
24 h. The reaction evolution was monitored by TLC (silica, MeCN:H2O: aqueous ammonia, 
6:3:1). The mixture was allowed to cool to room temperature and washed with ethanol (2 x 38 
mL) and ethyl ether (38 mL). This washing procedure was repeated twice.  
 
Reaction with acrylic acid. Compound
 
10: η = 79%. 1H-NMR (δppm, D2O): 7.49 (d, J= 8 Hz, 
H7,7’, 2H); 7.13 (d, J= 8 Hz, Ar-H, H8,8’, 2H); 6.07 (dd, J= 8-24 Hz, H10, 1H); 5.97 (d, J= 4 Hz, 
H8, 1H); 5.63 (d, J= 8 Hz, H9, 1H); 5.06 (s, H1, 7H); 3.91 (dd, J= 4-20 Hz, H3, 7H); 3.82 (s, H6, 
7H); 3.73 (s, H5, 7H); 3.63 (dd, J= 4-8 Hz, H4, 7H); 3.57 (dd, J= 8-20 Hz, H2, 7H).
 13
C-NMR 
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(δppm, D2O): 175.6 (C7), 133.9 (C8), 126.5 (C9), 101.9 (C1), 81.2 (C4), 73.1 (C3), 72.1 (C2), 71.9 
(C5), 60.3 (C6). EM [M+23] m/z 1242.4 (C48H74O37).
[48]
 (Appendix 2) 
Reaction with methacrylic acid. Compound
 
13: η=83% (is not complete pure). 1H-NMR 
(δppm, D2O): 5.65 (s, H8, 1H); 5.32 (s, H9, 1H); 4.96 (s, H1, 7H); 3.83-3.76 (m, H3,6, 21H); 3.65 (d, 
J=20 Hz, 7H); 3.54-3.44 (m, H4,2, 14H); 1.77 (s, 3H).
[48]
 (Appendix 3) 
 
3.2.2 Synthesis of compound 11 (2-monoacryloyl-β-CD)[49] 
To a stirred 0 ºC solution of β-CD (2 g, 1.76 mmol) dissolved in freshly distilled pyridine (22 
mL) was added dropwise an ice chilled solution of acryloyl chloride (0.32 mL, 3.88 mmol) in 
THF (1 mL). The solution was slowly warmed to room temperature then stirred for 16 h. 
Evaporation of solvent under reduced pressure afforded a white solid, which after 
recrystallization from ethanol. Compound
 
11: η= 94%. IR (KBr) υmax (cm
-1
): 3367.8 (OH), 
1726.4 (ROC(O)CHCH2). 
1
H-NMR (δppm, D2O): 6.33 (d, J=16 Hz, H8, 1H); 6.16-6.09 (m, H9’, 
1H); 5.93 (d, J=4 Hz, H9, 1H); 4.85 (s, H1, 7H); 
3.69-3.61 (m, H3,6, 21H); 3.58 (d, J= 8 Hz, H5, 7H); 
3.37-3.32 (m, H4,2, 14H).
 13
C-NMR (δppm, D2O): 
165.9 (C7), 132.4 (C9), 128.7 (C9), 102.4 (C1), 82.1 
(C4), 73.6 (C3), 72.9 (C2), 72.5 (C5), 60.4 (C6).
 1
H-
NMR (δppm, DMSO): 6.33 (d, J=4 Hz, H9’, 1H); 
6.21-6.14 (m, H8, 1H); 5.97-5.93 (m, H9, 1H); 5.83 
(s, OH2,3), 4.85 (s, H1, 7H); 4.45 (s, OH6) 3.68-3.64 
(m, H3,6, 21H); 3.59 (d, J= 8 Hz, H5, 7H); 3.45-3.16 
(m, H4,2, 14H).
[49]
 EM [M+23] m/z 1134.43 
(C42H70O35), 1242.39 (C45H72O36). (Appendix 4) 
 
 
Figure 3.2: Structure of product 11. 
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3.2.3 Synthesis of 12 (6-monoacryloly-heptakis-(2,3-di-O-benzyl)-β-CD) 
 
Figure 3.3: Synthetic scheme to obtain compound 12.  
 
3.2.3.1 Synthesis of persylation-β-cyclodextrins (4) [50] 
Dry β-CD (1 g, 0.88 mmol) was dissolved under vigorous stirring in dry pyridine (11 mL). 
The solution was cooled on an ice bath, producing a thick gel. A solution of TBDMSCl (1.60 g, 
10.2 mmol, 12 equiv.) in dry pyridine (16.6 mL) was then added dropwise to the cooled reaction 
over 3.5 h. During this time, the gel liquefied. Cooling was continued for a further 3 h before the 
solution was allowed to warm to room temperature. After a further 18 h at room temperature, the 
solvent was removed under reduced pressure to give a white solid, which was taken up in 
dichloromethane. The dichloromethane layer was washed with KHSO4 to remove any residual 
pyridine, follow by saturated aqueous NaCl solution. The organic solvent was evaporated. The 
product was purified by column chromatography with a gradient of solvents dichloromethane 
/methanol (9:1|8:2). Compound 4: η= 81%. 1H-NMR (δppm, CDCl3): 6.73 (s, H1, 7H); 5.27 (s, 
OH2, 7H); 4.89 (s, OH3, 7H); 4.04 (t, J= 9 Hz, H3, 7H); 3.90 (d, J= 9 Hz, H6, 14H); 3.71 (d, J= 11 
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Hz, H5, 7H); 3.63 (dd, J= 4-9 Hz, H4, 7H); 3.57 
(d, J= 8.8 Hz, H2, 7H); 0.87 (s, H10,11,12, 63H); 
0.04 (s, H7, 21H); 0.03 (s, H8, 21H).
[50]
 EM 
[M+23] m/z 1933.0 (C84H168O35Si7). (Appendix 
5) 
 
 
 
 
 
 
 
3.2.3.2 Synthesis of heptakis-(2,3-di-O-benzyl-6-tert-butydimethylsilyl)-β-CD (14) 
[51]
 
To a solution of compound 4 (1 g, 0.512 mmol) in dry DMF (16 mL) was added, at 0 ºC, 
NaH (0.60 g, 0.03 mmol). The suspension was allowed to stir at 0 ºC for 2 h, and then benzyl 
bromide (2.98 mL, 4.29 g, 0.03 mmol) was added. The reaction mixture was stirred for further 2 
h at 0 ºC and 12 h at room temperature and then 
quenched with methanol. The organic layer was 
extracted with pentane, washed with H2O, dried 
(Na2SO4) and finally the solvent was removed 
by distillation at reduced pressure. The product 
was purified by column chromatography with a 
gradient of solvents hexane/diethyl ether 
(15:1|10:1|8:2). Compound 14: η=43%. 1H-
NMR (δppm, CDCl3): 7.40– 7.05 (m, H15,16,17,18,19, 
70H); 5.32 (s, H1, 7H); 5.09 (d, J= 10.8Hz,14H, 
CH2, Bn-3); 4.71 (m, 14H, CH2, Bn-2); 4.51 (m, 
H3, 7H); 4.25 (d, J= 10 Hz, H6, 14H); 4.04 (dd, 
J= 9 Hz, H5, 7H); 3.72 (t, J= 10-12 Hz, H4, 7H); 
3.39 (d; J= 6.2 Hz, H2, 7H); 0.88 (s, 63H); 0.03 
(s, 21H); 0.02 (s, 21H).
[51]
 EM [M+23] m/z 3193.63 (C182H252O35Si7). (Appendix 6) 
 
 
Figure 3.4: Structure of product 4. 
 
Figure 3.5: Structure of product 14. 
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3.2.3.3 Synthesis of heptakis-(2,3-di-O-benzyl)-β-CD (15) [18] 
 Compound 14 (0.50 g, 0.16 mmol) was dissolved in dry THF (5 mL) then TBAF (0.57 g, 
2.20 mmol, 14 equiv.) was added and the reaction was carried out at room temperature during 24 
h. The solvent was evaporated and the final 
product was obtained after an ethyl acetate/water 
extraction. Compound 15: η= 94 %. 1H-NMR 
(δppm, CDCl3): 7.38– 7.15 (m, H9,10,11,12,13, 70H); 
5.06 (s, H1, 7H); 4.90 (d, J= 10.8Hz,14H, CH2, 
Bn-3); 4.67 (m, 14H, CH2, Bn-2); 4.52 (m, H3, 
7H); 3.99 (d, J= 6.5 Hz, H6, 14H); 3.78 (s, H5, 
7H); 3.65 (d, J= 7.7 Hz, H4, 7H); 3.49 (s, H2, 
7H).
 [18] 
(Appendix 7) 
 
 
 
3.2.3.4  Synthesis of 6-monoacryloly-heptakis-(2,3-di-O-benzyl)-β-CD (12): [49] 
The experimental procedure of this last step was the same described in chapter 3.2.2. 
Compound 15 (0.50 g, 0.21 mmol) dissolved in distilled pyridine (6 mL). Acryloyl chloride 
(0.04 mL, 0.46 mmol) dissolved in THF (0.3 mL). 
Compound 12: η=65%. IR (KBr) υmax (cm
-1
): 
3390.2 (OH), 1731.6 (ROC(O)CHCH2). 
1
H-NMR 
(δppm, DMSO-d6): 7.07–7.18 (m, H15,16,17,18,19, 70H); 
5.29 (s, H1, 7H); 4.51 and 4.49 (s, H13, 28H); 3.76-
3.92 (m, H3,6, 21H); 3.69 (s, H5, 7H); 3.35 (s, H2,4, 
14H). 
13
C-NMR (δppm, DMSO-d6): 128.9-127.6 
(C14,15,16,17,18,19), 97.1 (C1), 88.0 (C3), 79.0 (C2), 77.0 
(C4), 74.0 (C5), 69.0 (C13), 60.5 (C6). EM [M+23] 
m/z 2529.1 (C143H156O36 + C5H5N), 2583.1 
(C151H163O37 + C5H5N).
 [49]
 (Appendix 8) 
 
 
 
Figure 3.6: Structure of product 15. 
 
Figure 3.7: Structure of product 12. 
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Figure 3.9: Reaction between the acid anhydride and benzotriazole to obtain product 17. 
3.2.4 Synthesis of acetylation β-CD 
Method A 
[52]
   
To a solution of β-CD (1 g, 0.88 mmol) in DMF (40 mL) was added ethyldiisopropylamine 
(6.48 mmol, 1.11 mL, 7 equiv.). A solution of acetyl chloride (0.43 mL, 6.17 mmol, 7 equiv) in 
DMF (10 mL) was slowly added for 2 h at -30 ºC. The mixture was left to stand for 14 h at 20 ºC, 
concentrated in vacuum, and treated with 100 mL of dichloromethane. The precipitate formed 
was filtered off, washed with dichloromethane and dried in vacuum. Compound
 
16: η= 89 %. 
1
H-NMR (δppm, DMSO-d6): 4.97 (s, H1, 7H); 3.97-3.77 (m, H3,6,5, 28H); 3.64-3.49 (m, H4,2, 14H); 
2.16 (s, H8, 3H). EM [M+23] m/z 1134.43 (C42H70O35), 1176.38 (C44H72O36), 1218.39 
(C46H74O37), 1260.40 (C48H76O38), 1302.41 
(C50H78O39), 1344.42 (C52H80O40).  
The same procedure was repeated but with 
10 equivalents of ethyldiisopropylamine (8.81 
mmol, 0.63 mL) and acetyl chloride (0.61 mL, 
8.81 mmol). η= 75 %. 1H-NMR (δppm, DMSO-
d6): 4.98 (s, H1, 7H); 4.15-3.77 (m, H3,6,5, 28H); 
3.64-3.49 (m, H4,2, 14H); 2.20-2.04 (d, J= 7.6 
Hz, H8, 21H).
 [52]
 EM [M+23] m/z 1157.4 
(C42H70O35), 1176.3 (C44H72O36), 1218.4 
(C46H74O37), 1260.4 (C48H76O38), 1302.4 
(C50H78O39), 1344.4 (C52H80O40), 1386.4 
(C54H82O41), 1428.4 (C54H82O42).
 
(Appendix 9) 
 
 
Method B 
[53]
 
B.1. Procedure for the preparation of compound 22 (1-(1H-1,2,3-Benzotriazol-
1-yl)-1-ethanone) 
 
Figure 3.8: Structure of product 16. 
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A solution of the benzotriazole (0.24 g, 2.00 mmol) in dry dichloromethane (10 mL) was 
treated with diisopropylethylamine (2.50 mmol, 0.43 mL) followed by the dropwise addition of a 
solution of acetic anhydride (0.21 mL, 0.22 g, 2.20 mmol) in dichloromethane (2 mL) at 0 ºC. 
The resulting mixture was allowed to warm to room temperature and stirred a further 2 h. The 
reaction mixture was then quenched with H2O (20 mL) and extracted with ethyl acetate (2 x 20 
mL). The combined organic layers were washed with brine (10 mL) and dried over anhydrous 
Na2SO4. The solvent was removed and the obtained product dried in vacuum. Compound
 
17: η= 
72%.
 1
H-NMR (δppm, D2O): 7.79 (d, J= 2.5 Hz, Ar-H, 2H); 7.18 (d, J= 1.7 Hz, Ar-H, 2H); 3.00 (s, 
CH3, 3H).
[53]
 (Appendix 10) 
 
B.2. 6-Peracetylation-β-CD (18) [53] 
To a solution of β-CD (0.25 g, 0.22 mmol), in DMF (10 mL) was added sodium hydride (74.0 
mg, 3.08 mmol, 14 equiv). After 2 h 30 min stirring at room temperature a solution of compound 
17 (0.50 g, 3.08 mmol, 14 equiv.) in dry DMF (1 
mL) was added. After 16 h, the solvent was 
evaporated and dichloromethane was added. The 
resulting precipitate was recovered by suction 
filtration and washed with dichloromethane. 
Compound
 
18: 
1
H-NMR (δppm, D2O): 7.77 (d, 
J= 2.5 Hz, Ar-H, 2H); 7.23 (d, J= 1.7 Hz, Ar-H, 
2H); 4.92 (s, H1, 7H); 3.70 (m, H3,6,5, 28H); 3.50 
(m, H4,2, 14H); 2.00 (s, H8, 3H).
[53] 
EM [M+23] 
m/z 1283.5 (C50H78O39), 1325.5 (C50H78O39), 
1367.5 (C52H80O40), 1409.5 (C54H82O41), 1451.5 
(C56H84O42). (Appendix 11) 
 
 
 
 
 
 
 
 
 
Figure 3.10: Structure of product 18. 
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B.3. 6-Monoacetly-β-CD (19) 
To a solution of β-CD (0.25 g, 0.22 mmol), in DMF (10 mL) was added sodium hydride (0.01 
g, 0.44 mmol, 2 equiv.). After 2 h 30 minutes under magnetic stirring, at room temperature, a 
solution of compound 17 (0.07 g, 0.44 mmol, 2 
equiv.) in dry DMF (1 mL) was added. After 2 
h, the solvent was evaporated and 
dichloromethane was added. The resulting 
precipitate was recovered by suction filtration 
and washed with dichloromethane. Compound
 
19: 
1
H-NMR (δppm, D2O): 7.79 (d, J= 2.5 Hz, 
Ar-H, 2H); 7.18 (d, J=1.7 Hz, Ar-H, 2H); 4.93 
(s, H1, 7H); 3.86-3.69 (m, H3,6,5, 28H); 3.52-3.44 
(m, H4,2, 14H); 2.05 (s, H8, 3H). EM [M+23] 
m/z 1157.3 (C42H70O35), 1199.4 (C44H72O36), 
1241.2 (C46H74O37), 1283.3 (C48H76O38). 
(Appendix 12) 
 
3.3 Studies in scCO2 
3.3.1 General methods for co-polymer synthesis in scCO2 
Polymerizations reactions were carried out in 33 ml stainless steel high-pressure cell 
equipped with two aligned sapphire windows, which allow full visualization of the reaction 
mixture. The cell was loaded with reactants: monomers (MAA and NIPAAm, 1:3), modified β-
CD (when used 2.5% and 8.8%), crosslinker (1% EGDMA), initiator (AIBN). The cell is sealed 
and purged. Liquid carbon dioxide is loaded into the cell using a high-pressure compressor 
(NWA GmbH). Then the cell was immersed in water bath set to 65ºC, with a stability ± 0.01ºC. 
Temperature control was made through a resistance temperature detector probe contacting the 
cell, connected to a Hart Scientific PID controller. Stirring was achieved by means of a Teflon 
coated magnetic bar. Carbon dioxide was added up to 240 bar. Polymerization reactions 
proceeded for 24 hours under stirring. It could be seen through the sapphire windows that all 
polymerization started as a completely homogenous phase, with all reactants completely 
dissolved in scCO2. At the end of the reaction, the polymers were slowly washed with fresh high-
pressure CO2 in order to clean any unreacted residues. Upon venting a fluffy, dry, white, free-
 
Figure 3.11: Structure of product 19. 
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flowing powder remained in the reaction vessel. The polymer yield was determined 
gravimetrically. 
4.3.1.1. The first test was the co-polymer without β-CD. 
4.3.1.2. The second test was made with 10 (2.5%). η= 77.4 %. 1H-HR-MAS-NMR (δppm, 
DMSO-d6): 7.22 (s, polymer); 5.75 (s, polymer); 4.83 (s, H1, 7H); 3.86 (s, H3, 7H); 3.58 (t, J=12-
24 Hz, H6, 14H); 3.44 (s, H5, 7H); 3.37-3.19 (m, H4,2, 14H); 1.96 (s, polymer); 1.00 (s, polymer). 
(Appendix 13) RXD: Chapter 2, Figure 2.21. 
4.3.1.3. The third test was with 11 (2.5%).
 η= 78.2 %. RXD: Chapter 2, Figure 2.22. 
4.3.1.4. The fourth test the 12 was used (2.5%). η= 65.3 %. 1H-HR-MAS-NMR (δppm, 
DMSO-d6): 7.13 (m, H15,16,17,18,19, 70H); 5.29 (s, H1, 7H); 3.83 (m, H3,6,5, 28); 2.51(s, H4,2, 14H); 
1.06 (m, polymer). (Appendix 14) 
4.3.1.4. The last test was with 11 (8.8%). η= 79.6 %. 1H-HR-MAS-NMR (δppm, D2O/DMSO-
d6): 6.21-5.97 (m, H9,9’,8, 3H); 5.74-5.69 (m, OH2,3, 13H); 4.82 (s, H1, 7H); 4.50 (s, OH6, 7H); 
3.92-3.81 (m, polymer); 3.65-3.55 (m, H3,6,5, 28); 3.48 (s, H4, 7H); 3.35 (d, J= 9Hz, H2, 7H); 1.22-
1.04 (m, polymer). (Appendix 15)  
3.3.2 General methods for scCO2-assisted impregnation 
The impregnation of a model drug, into the co-polymers was performed at 65 ºC and 240 bar 
within 20 h, in a cell similar to that of the polymerization, with a porous support which divides 
the cell in two compartments. This prevents physical contact between the drug and the samples. 
The drug was placed in the downer compartment, under the porous support with a magnetic 
stirrer bar, and in quantity enough to obtain a saturated solution at the p, T impregnation 
conditions. The polymers were loaded into cellulose membranes (cutoff 3.5 KDa) which were 
placed in the upper compartment of the cell. At the end of the impregnation period the system 
was quickly depressurized. Impregnated drug was calculated gravimetrically by weighting the 
membranes in a Sartorious balance (precision ± 0.00001 g). 
This study was realized with the metronidazole. (Chapter 2, Table 2.3) 
 
3.3.3 General methods for in vitro drug release experiments 
After impregnation, the polymers were transferred to porous membranes and put in buffer 
solution at pH 2.2 (HCl-Glycine) and at 7.4 (Phosphate Buffered Saline) at controlled 
temperature 37 ºC. 1 ml aliquots were withdrawn at time intervals and the same volume of fresh 
medium was added to the solution. Quantification was performed by making a calibration curve 
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in a spectrophotometer at 265 nm and the total mass released was determined considering the 
aliquots and the dilution produced by addition of fresh buffer solution. The results at different 
pHs are presented in Tables 3.1 e 3.2. 
Table 3.1: Results of metronidazole release of each co-polymer at pH 2.2. 
 Drug Release (mg/g) at pH 2.2 
Time 
(h) 
Co-polymer 
without β-CD  
Co-polymer 
10 (2.5%) 
Co-polymer 
11 (2.5%) 
Co-polymer 
11 (8.8%) 
Co-polymer 
12 (2.5%) 
0.00 0.62 0.66 0.38 3.61 0.15 
0.17 3.20 4.28 1.53 14.41 0.69 
0.33 4.39 6.05 4.22 21.15 3.15 
0.50 5.11 7.36 5.79 21.24 4.00 
0.67 5.62 8.51 6.58 - 4.28 
0.83 5.98 9.17 7.74 24.47 4.69 
1.08 6.31 9.64 8.90 24.94 4.82 
1.33 6.64 10.13 10.07 27.40 5.10 
1.62 6.80 10.29 10.85 27.42 4.04 
1.93 6.83 10.61 11.25 27.29 5.10 
2.27 6.83 10.77 11.64 28.15 5.10 
2.60 6.80 10.61 12.02 29.38 5.12 
3.10 6.80 10.61 12.41 28.77 5.12 
3.60 6.80 10.44 12.42 30.16 4.97 
4.43 7.25 10.44 12.80 30.37 4.97 
5.43 - - - 30.36 - 
6.43 - - - 31.10 - 
7.43 - - - 30.61 - 
8.43 - - - 33.05 - 
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Table 3.2: Results of metronidazole release of each co-polymer at pH 7.4. 
 Drug Release (mg/g) at pH 7.4 
Time 
(h) 
Co-polymer 
without β-CD 
Co-polymer 
10 (2.5%) 
Co-polymer 
11 (2.5%) 
Co-polymer 
11 (8.8%) 
Co-polymer 
12 (2.5%) 
0.00 0.00 0.18 0.00 0.00 0.45 
0.17 5.76 1.58 5.86 4.74 1.22 
0.33 7.12 2.81 11.01 6.90 2.12 
0.50 8.93 4.03 - 8.40 2.59 
0.67 9.63 4.38 - 10.50 2.89 
0.83 10.35 4.73 14.55 11.51 3.04 
1.08 11.04 5.26 15.27 11.17 3.20 
1.33 11.39 5.26 15.81 13.96 3.33 
1.62 11.74 5.44 15.97 14.98 3.33 
1.93 11.75 5.61 16.17 15.61 3.65 
2.27 12.09 5.61 15.79 16.96 3.65 
2.60 11.76 5.61 15.96 18.69 3.49 
3.10 12.10 5.61 15.77 19.69 3.49 
3.60 12.09 5.79 15.58 21.42 3.49 
4.43 11.76 5.44 15.39 22.42 3.65 
5.43 - - - 23.78 - 
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